<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.1?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?covid-19-tdm?>
<?properties open_access?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Database (Oxford)</journal-id>
    <journal-id journal-id-type="iso-abbrev">Database (Oxford)</journal-id>
    <journal-id journal-id-type="publisher-id">databa</journal-id>
    <journal-title-group>
      <journal-title>Database: The Journal of Biological Databases and Curation</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1758-0463</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
      <publisher-loc>UK</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">8011435</article-id>
    <article-id pub-id-type="pmid">33787872</article-id>
    <article-id pub-id-type="doi">10.1093/database/baab017</article-id>
    <article-id pub-id-type="publisher-id">baab017</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Original Article</subject>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00960</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Drugmonizome and Drugmonizome-ML: integration and abstraction of
small molecule attributes for drug enrichment analysis and machine
learning</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Kropiwnicki</surname>
          <given-names>Eryk</given-names>
        </name>
        <xref rid="FN001" ref-type="author-notes"/>
        <aff><institution content-type="department">Department of Pharmacological
Sciences; Mount Sinai Center for Bioinformatics; Big Data to Knowledge,
Library of Integrated Network-Based Cellular Signatures, Data
Coordination and Integration Center (BD2K-LINCS DCIC); Knowledge
Management Center for Illuminating the Druggable Genome (KMC-IDG); Icahn
School of Medicine at Mount Sinai</institution>, 1 Gustave L. Levy
Place, Box 1603, New York, NY 10029, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4836-0518</contrib-id>
        <name>
          <surname>Evangelista</surname>
          <given-names>John E</given-names>
        </name>
        <xref rid="FN001" ref-type="author-notes"/>
        <aff><institution content-type="department">Department of Pharmacological
Sciences; Mount Sinai Center for Bioinformatics; Big Data to Knowledge,
Library of Integrated Network-Based Cellular Signatures, Data
Coordination and Integration Center (BD2K-LINCS DCIC); Knowledge
Management Center for Illuminating the Druggable Genome (KMC-IDG); Icahn
School of Medicine at Mount Sinai</institution>, 1 Gustave L. Levy
Place, Box 1603, New York, NY 10029, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Stein</surname>
          <given-names>Daniel J</given-names>
        </name>
        <aff><institution content-type="department">Department of Pharmacological
Sciences; Mount Sinai Center for Bioinformatics; Big Data to Knowledge,
Library of Integrated Network-Based Cellular Signatures, Data
Coordination and Integration Center (BD2K-LINCS DCIC); Knowledge
Management Center for Illuminating the Druggable Genome (KMC-IDG); Icahn
School of Medicine at Mount Sinai</institution>, 1 Gustave L. Levy
Place, Box 1603, New York, NY 10029, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Clarke</surname>
          <given-names>Daniel J B</given-names>
        </name>
        <aff><institution content-type="department">Department of Pharmacological
Sciences; Mount Sinai Center for Bioinformatics; Big Data to Knowledge,
Library of Integrated Network-Based Cellular Signatures, Data
Coordination and Integration Center (BD2K-LINCS DCIC); Knowledge
Management Center for Illuminating the Druggable Genome (KMC-IDG); Icahn
School of Medicine at Mount Sinai</institution>, 1 Gustave L. Levy
Place, Box 1603, New York, NY 10029, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1982-7652</contrib-id>
        <name>
          <surname>Lachmann</surname>
          <given-names>Alexander</given-names>
        </name>
        <aff><institution content-type="department">Department of Pharmacological
Sciences; Mount Sinai Center for Bioinformatics; Big Data to Knowledge,
Library of Integrated Network-Based Cellular Signatures, Data
Coordination and Integration Center (BD2K-LINCS DCIC); Knowledge
Management Center for Illuminating the Druggable Genome (KMC-IDG); Icahn
School of Medicine at Mount Sinai</institution>, 1 Gustave L. Levy
Place, Box 1603, New York, NY 10029, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7812-7752</contrib-id>
        <name>
          <surname>Kuleshov</surname>
          <given-names>Maxim V</given-names>
        </name>
        <aff><institution content-type="department">Department of Pharmacological
Sciences; Mount Sinai Center for Bioinformatics; Big Data to Knowledge,
Library of Integrated Network-Based Cellular Signatures, Data
Coordination and Integration Center (BD2K-LINCS DCIC); Knowledge
Management Center for Illuminating the Druggable Genome (KMC-IDG); Icahn
School of Medicine at Mount Sinai</institution>, 1 Gustave L. Levy
Place, Box 1603, New York, NY 10029, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Jeon</surname>
          <given-names>Minji</given-names>
        </name>
        <aff><institution content-type="department">Department of Pharmacological
Sciences; Mount Sinai Center for Bioinformatics; Big Data to Knowledge,
Library of Integrated Network-Based Cellular Signatures, Data
Coordination and Integration Center (BD2K-LINCS DCIC); Knowledge
Management Center for Illuminating the Druggable Genome (KMC-IDG); Icahn
School of Medicine at Mount Sinai</institution>, 1 Gustave L. Levy
Place, Box 1603, New York, NY 10029, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2755-2097</contrib-id>
        <name>
          <surname>Jagodnik</surname>
          <given-names>Kathleen M</given-names>
        </name>
        <aff><institution content-type="department">Department of Pharmacological
Sciences; Mount Sinai Center for Bioinformatics; Big Data to Knowledge,
Library of Integrated Network-Based Cellular Signatures, Data
Coordination and Integration Center (BD2K-LINCS DCIC); Knowledge
Management Center for Illuminating the Druggable Genome (KMC-IDG); Icahn
School of Medicine at Mount Sinai</institution>, 1 Gustave L. Levy
Place, Box 1603, New York, NY 10029, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Ma’ayan</surname>
          <given-names>Avi</given-names>
        </name>
        <!--avi.maayan@mssm.edu-->
        <xref rid="COR0001" ref-type="corresp"/>
        <aff><institution content-type="department">Department of Pharmacological
Sciences; Mount Sinai Center for Bioinformatics; Big Data to Knowledge,
Library of Integrated Network-Based Cellular Signatures, Data
Coordination and Integration Center (BD2K-LINCS DCIC); Knowledge
Management Center for Illuminating the Druggable Genome (KMC-IDG); Icahn
School of Medicine at Mount Sinai</institution>, 1 Gustave L. Levy
Place, Box 1603, New York, NY 10029, <country country="US">USA</country></aff>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR0001">*Corresponding author: Tel: 212-241-1153; Fax:
212-849-2456; Email: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="avi.maayan@mssm.edu">avi.maayan@mssm.edu</email></corresp>
      <fn id="FN001">
        <label>
          <sup>†</sup>
        </label>
        <p>Eryk Kropiwnicki, John E. Evangelista contributed equally to this work.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="epub" iso-8601-date="2021-03-31">
      <day>31</day>
      <month>3</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>31</day>
      <month>3</month>
      <year>2021</year>
    </pub-date>
    <elocation-id>baab017</elocation-id>
    <history>
      <date date-type="received">
        <day>25</day>
        <month>11</month>
        <year>2020</year>
      </date>
      <date date-type="rev-recd">
        <day>11</day>
        <month>3</month>
        <year>2021</year>
      </date>
      <date date-type="accepted">
        <day>19</day>
        <month>3</month>
        <year>2021</year>
      </date>
      <date date-type="editorial-decision">
        <day>17</day>
        <month>3</month>
        <year>2021</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2021. Published by Oxford University
Press.</copyright-statement>
      <copyright-year>2021</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits
unrestricted reuse, distribution, and reproduction in any medium, provided
the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="baab017.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Understanding the underlying molecular and structural similarities between
seemingly heterogeneous sets of drugs can aid in identifying drug repurposing
opportunities and assist in the discovery of novel properties of preclinical
small molecules. A wealth of information about drug and small molecule
structure, targets, indications and side effects; induced gene expression
signatures; and other attributes are publicly available through web-based tools,
databases and repositories. By processing, abstracting and aggregating
information from these resources into drug set libraries, knowledge about novel
properties of drugs and small molecules can be systematically imputed with
machine learning. In addition, drug set libraries can be used as the underlying
database for drug set enrichment analysis. Here, we present Drugmonizome, a
database with a search engine for querying annotated sets of drugs and small
molecules for performing drug set enrichment analysis. Utilizing the data within
Drugmonizome, we also developed Drugmonizome-ML. Drugmonizome-ML enables users
to construct customized machine learning pipelines using the drug set libraries
from Drugmonizome. To demonstrate the utility of Drugmonizome, drug sets from 12
independent SARS-CoV-2 <italic toggle="yes">in vitro</italic> screens were subjected to
consensus enrichment analysis. Despite the low overlap among these 12
independent <italic toggle="yes">in vitro</italic> screens, we identified common biological
processes critical for blocking viral replication. To demonstrate
Drugmonizome-ML, we constructed a machine learning pipeline to predict whether
approved and preclinical drugs may induce peripheral neuropathy as a potential
side effect. Overall, the Drugmonizome and Drugmonizome-ML resources provide
rich and diverse knowledge about drugs and small molecules for direct systems
pharmacology applications.</p>
      <p><bold>Database URL</bold>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://maayanlab.cloud/drugmonizome/" ext-link-type="uri">https://maayanlab.cloud/drugmonizome/</ext-link>.</p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Institutes of Health</institution>
            <institution-id institution-id-type="DOI">10.13039/100000002</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>U24CA224260, U54HL127624, OT2OD030160</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="13"/>
    </counts>
    <custom-meta-group>
      <custom-meta>
        <meta-name>article-lifecycle</meta-name>
        <meta-value>PAP</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="s1">
    <title>Introduction</title>
    <p>Currently, drug discovery efforts suffer from high attrition rates, long research and
development timelines, and high financial costs (<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R2" ref-type="bibr">2</xref>). Big Data applications to
drug discovery include <italic toggle="yes">in silico</italic> docking drug screens,
network-based and transcriptomics-based methods, as well as the combination of
<italic toggle="yes">in vitro</italic> screens with computational predictions (<xref rid="R3" ref-type="bibr">3</xref>, <xref rid="R4" ref-type="bibr">4</xref>).
Drug repurposing is a strategy for elucidating novel indications for previously
approved compounds with known safety profiles. This approach significantly mitigates
the conventional drug discovery life cycle (<xref rid="R5" ref-type="bibr">5</xref>,
<xref rid="R6" ref-type="bibr">6</xref>). The process of drug repurposing
usually involves the high-throughput screening of a library of approved and
preclinical compounds to observe a particular desired phenotype. Such screens
identify and prioritize potential therapeutic leads. The identified lead compounds
may be a heterogeneous group of small molecules whose common mechanisms of action
are unclear. <italic toggle="yes">In vitro</italic> screening techniques can be supplemented with
computational methods to further investigate the connectedness among the top small
molecule hits.</p>
    <p>At the same time, gene set enrichment analysis (<xref rid="R7" ref-type="bibr">7</xref>) is a popular statistical method that computes significant overlap
between an input gene set and libraries of annotated gene sets. Several online tools
such as Enrichr (<xref rid="R8" ref-type="bibr">8</xref>, <xref rid="R9" ref-type="bibr">9</xref>), WebGestalt (<xref rid="R10" ref-type="bibr">10</xref>) and
DAVID (<xref rid="R11" ref-type="bibr">11</xref>) have used this paradigm to enable
users to better understand their results from genomics, transcriptomics,
epigenomics, proteomics and other omics. Enrichment analysis can be applied to drug
and small molecule sets in a similar way. For example, drug set enrichment analysis
was applied to analyze drug-induced gene expression profiles of small molecules that
shared a phenotype of interest (<xref rid="R12" ref-type="bibr">12</xref>). Huang
<italic toggle="yes">et al.</italic> expanded on the idea of drug set enrichment analysis by
developing a tool called DrugPattern (<xref rid="R13" ref-type="bibr">13</xref>).
DrugPattern analyzes drug sets, where a set of drugs is grouped under a common
biomedical term. DrugPattern was demonstrated to predict drugs that may downregulate
oxidized low-density lipoprotein, a molecule associated with the development of
coronary heart disease. Predictions for novel compounds were confirmed <italic toggle="yes">in
vitro</italic>. These two previous efforts to develop drug set enrichment
analysis tools establish a good foundation for such analyses. However, these
resources suffer from low coverage of unique small molecules and their associated
biomedical attributes, as well as outdated web-based platforms that are not
intuitive to use.</p>
    <p>Here, we expand on previous drug set enrichment analysis efforts with Drugmonizome
and Drugmonizome-ML. Drugmonizome is a database with a web-based interface for
querying sets of small molecules and drugs to retrieve enriched biomedical terms. In
contrast to prior tools, the drug set libraries within Drugmonizome are extracted
from many more resources. In addition, the user interface of Drugmonizome provides
fast enrichment analysis calculation, complex metadata queries and interactive
visualization of the enrichment results, among other advanced features.
Drugmonizome-ML is an interactive machine learning pipeline that is a counterpart to
Drugmonizome. Drugmonizome-ML provides users with flexible options for creating
customized machine learning models to predict novel attributes for small molecules
and drugs, for example, side effects or indications.</p>
    <p>The utility of Drugmonizome and Drugmonizome-ML is demonstrated via two case studies.
To showcase the capabilities of Drugmonizome, we performed meta-analysis of 12
published <italic toggle="yes">in vitro</italic> drug screens to identify consensus features of
compounds found to be effective against the coronavirus SARS-CoV-2. A case study
that utilizes Drugmonizome-ML predicts whether preclinical small-molecule compounds
and approved drugs will induce peripheral neuropathy as a side effect, based on
transcriptomics and compound structural features.</p>
  </sec>
  <sec id="s2">
    <title>Materials and methods</title>
    <sec id="s2-s1">
      <title>Harmonizing small molecule names and identifiers</title>
      <p>Due to the inherent inconsistencies in the way small molecules and drugs are
cataloged across various online repositories (<xref rid="R14" ref-type="bibr">14</xref>, <xref rid="R15" ref-type="bibr">15</xref>), resolving unique
small molecule entities among these resources required a standardized lexicon of
small molecule names and synonyms. Previous efforts used the UniChem
connectivity search (<xref rid="R16" ref-type="bibr">16</xref>) to map
International Union of Pure and Applied Chemistry Chemical Identifier (InChI)
key representations of small molecules from DrugBank (<xref rid="R17" ref-type="bibr">17</xref>) to unique identifiers from a variety of drug cataloging
resources (<xref rid="R18" ref-type="bibr">18</xref>). The InChIKey is a widely
used text-based identifier system for chemicals. The DrugBank database currently
includes over 12 000 well-studied approved drugs and experimental small
molecules that are annotated with a variety of metadata (<xref rid="R17" ref-type="bibr">17</xref>). Therefore, identifiers from popular chemical
cataloging resources such as PubChem (<xref rid="R19" ref-type="bibr">19</xref>)
and PharmGKB (<xref rid="R20" ref-type="bibr">20</xref>) could be
cross-referenced with DrugBank to harmonize and standardize small molecule names
and synonyms. This same methodology was adapted for the 2019 version of
DrugBank. For this project, we created a master metadata table of small
molecules and their associated identifiers. This includes synonymous names;
InChIKeys; canonical simplified molecular-input line-entry system (SMILES)
strings, an ASCII representation of small molecule structure; and
resource-specific identifiers from DrugBank. In addition, experimental small
molecules that were unique to the library of network-based cellular signatures
(LINCS) project (<xref rid="R21" ref-type="bibr">21</xref>) were included in the
master metadata table with their resource-specific identifiers. If any of these
small molecule identifiers were not cataloged in DrugBank or the LINCS Common
Fund program, we queried PubChem with the power user gateway-representational
state transfer (PUG-REST) (<xref rid="R22" ref-type="bibr">22</xref>)
application programming interface (API) (<xref rid="R23" ref-type="bibr">23</xref>) to retrieve the missing small molecule metadata. In addition,
experimental small molecules that were unique to the LINCS project (<xref rid="R21" ref-type="bibr">21</xref>) were included in the master metadata
table with their resource-specific identifiers.</p>
    </sec>
    <sec id="s2-s2">
      <title>Creating the drug set libraries</title>
      <p>Drug set libraries associate biomedical terms with drugs and small molecules.
Drug set libraries are stored as drug matrix transposed (.DMT) files, a tab
delimited file format that describes a collection of term–drug set
associations. The 34 Drugmonizome drug set libraries contain drug–term
associations collected from various online tools and repositories. We required
that each set of drugs must include at least five small molecules. This
requirement is to satisfy the minimum requirement for contingency table
statistics with the Fisher’s exact test (<xref rid="R24" ref-type="bibr">24</xref>). Python scripts and Jupyter Notebooks were developed to process
the data from each resource. These open-source pipelines generate the drug set
libraries. Drug set libraries can be grouped into several categories that
include (i) drug targets and associated genes; (ii) side effects, adverse events
and phenotypes; (iii) gene ontology (GO) and pathway terms; (iv) chemical
structure and sub-structure motifs; and (v) modes of action. Drug targets and
drug–gene co-occurrences from literature were collected from several
sources including (i) the Drug Repurposing Hub (<xref rid="R25" ref-type="bibr">25</xref>); (ii) DrugBank (<xref rid="R17" ref-type="bibr">17</xref>);
(iii) DrugCentral (<xref rid="R26" ref-type="bibr">26</xref>); (iv) Harvard
Medical School LINCS KINOMEScan (<xref rid="R27" ref-type="bibr">27</xref>) and
(v) Geneshot (<xref rid="R28" ref-type="bibr">28</xref>). Drug-induced gene
expression signatures were extracted from (vi) L1000 fireworks display
(L1000FWD) (<xref rid="R29" ref-type="bibr">29</xref>); (vii) CREEDS (<xref rid="R30" ref-type="bibr">30</xref>) and (viii) search tool for interactions
of chemicals (STITCH) (<xref rid="R15" ref-type="bibr">15</xref>). Drug to
single nucleotide variant associations were extracted and processed from
PharmGKB (<xref rid="R20" ref-type="bibr">20</xref>). Side effect information
was collected from (i) Side Effect Resource (SIDER) (<xref rid="R31" ref-type="bibr">31</xref>); (ii) predicted side effects from the side effect
prediction (SEP)-L1000 (<xref rid="R32" ref-type="bibr">32</xref>); and
predicted side effects were also curated from (iii) OFFSIDES (<xref rid="R33" ref-type="bibr">33</xref>). Gene ontology terms were extracted
from the Gene Ontology (<xref rid="R34" ref-type="bibr">34</xref>), and pathway
terms were extracted from KEGG (<xref rid="R35" ref-type="bibr">35</xref>).
These terms were associated with unique small molecules based on gene expression
profiles. Upregulated and downregulated gene sets for each small molecule were
separately queried via the Enrichr API (<xref rid="R8" ref-type="bibr">8</xref>,
<xref rid="R9" ref-type="bibr">9</xref>). Term–drug pairs with a
significant <italic toggle="yes">q</italic>-value (Benjamini–Hochberg correction,
<italic toggle="yes">P</italic> &lt; 0.01) were included in the drug
set library. Small molecules were grouped under their common upregulated or
downregulated GO or pathway terms. Mechanisms of action and clinical indications
for drugs were collected from (i) World Health Organization Anatomical
Therapeutic Chemical (ATC) codes (<xref rid="R36" ref-type="bibr">36</xref>);
(ii) The Drug Repurposing Hub (<xref rid="R25" ref-type="bibr">25</xref>) and
(iii) SIDER (<xref rid="R31" ref-type="bibr">31</xref>). Finally, we grouped the
drugs and small molecules by their shared structural features. As described
above, a master list of every unique small molecule, and its metadata, retrieved
across all resources was created. This master list included SMILES. RDKit is an
open-source cheminformatics package capable of decomposing SMILES strings into
descriptive bit vectors that describe the molecular features of a small molecule
(<xref rid="R37" ref-type="bibr">37</xref>). The SMILES string of each small
molecule from the Drugmonizome master list was converted into a bit vector array
using the 166-bit Molecular ACCess System (MACCS) key dictionary (<xref rid="R38" ref-type="bibr">38</xref>) and the 881-bit PubChem fingerprint
dictionary. Small molecules sharing the same bits corresponding to a common
structural feature were grouped into sets and converted into respective MACCS
and PubChem fingerprint drug set libraries.</p>
    </sec>
    <sec id="s2-s3">
      <title>The Drugmonizome user interface</title>
      <p>The Drugmonizome web-based application is built on an instance of the Signature
Commons (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/MaayanLab/signature-commons" ext-link-type="uri">https://github.com/MaayanLab/signature-commons</ext-link>). The Signature
Commons software architecture is a skeleton general-purpose cataloging system
with signature search capabilities. The Signature Commons database employs a
hierarchical cross-referencing system that relies on universally unique
identifiers attached to each unique resource, drug set library, drug set within
each library, and small molecule entity within each of the drug sets. The front
page includes a metadata search, where users can submit queries to retrieve
information about single drugs and any search term found within descriptions of
resources, libraries, drug sets and small molecules. The drug set enrichment
analysis page enables users to submit a set of small molecule entities for
enrichment analysis. These entities need to be entered as one entity in each row
and can be a drug name, an InChIKey, a DrugBank ID, a Broad Institute (BRD)
identifier or a SMILES string, depending on the level of specificity the user
requires for the search. Entities within the Drugmonizome database may share the
same name, although their stereochemistry may differ, as denoted by their
associated InChIKey. If users are concerned with stereochemistry, they may opt
to submit their queries as DrugBank ID, BRD-ID or InChIKey. Once the entity list
is submitted, a results page is generated with identified enriched drug sets
across all resources. Users can expand each resource to view the enrichment
results from each drug set library. The specific enriched drug sets and
overlapping small molecule entities are displayed in bar charts, volcano plots
and interactive sortable tables. The resources page includes all the tools,
databases and repositories from which the Drugmonizome data were compiled.
Clicking on any of the resource cards directs users to a page that describes the
resource. The ‘Tutorial’ and ‘API’ tabs include
documentation for using the Drugmonizome website and API. Lastly, the
‘About’ page includes a variety of global statistics that
visualize the coverage of biomedical terms and drug–term associations in
Drugmonizome, including pie charts that visualize the relative contributions of
each resource to the overall database.</p>
    </sec>
    <sec id="s2-s4">
      <title>Computing drug set enrichment</title>
      <p>The Fisher’s exact test (<xref rid="R24" ref-type="bibr">24</xref>) is the
core method used to calculate the significance of overlap between two drug sets.
It calculates the probability of observing overlap between two independent sets
based on the hypergeometric distribution. Drugmonizome utilizes an
implementation of the Fisher’s exact test that is optimized for speed.
The enrichment analysis component, accessible via an API, is implemented as an
independent Java servlet running on a Dockerized Apache Tomcat server.</p>
    </sec>
    <sec id="s2-s5">
      <title>Creating the Drugmonizome-ML Appyter</title>
      <p>Appyters are self-contained web-based bioinformatics applications that are
created directly from Jupyter Notebooks (<xref rid="R39" ref-type="bibr">39</xref>). By inserting Jinja syntax into a Jupyter Notebook, the notebook
becomes a template. This template is compiled into a full-stack Dockerized
web-based application that presents the user with an HTML form that collects
global variables needed for the notebook execution. Once the user fills the form
and clicks submit, the notebook is executed in the cloud and the user is
presented with the rendered executed notebook. The Drugmonizome-ML Appyter is an
interactive web-based bioinformatics application built on top of the
Drugmonizome database. The Drugmonizome-ML Appyter input form is composed of
three sections: input dataset selection, target label selection and settings for
the machine learning pipelines. Input features include all the drug set
libraries included in Drugmonizome, as well as other datasets. Specifically, the
Drugmonizome-ML Appyter includes features extracted from SEP-L1000 (<xref rid="R32" ref-type="bibr">32</xref>). These features include L1000 gene
expression signatures (<xref rid="R40" ref-type="bibr">40</xref>), cell
morphological features (<xref rid="R41" ref-type="bibr">41</xref>) and chemical
fingerprints. The target label selection provides users with the ability to
specify the target vector for predictions such as side effects, drug targets and
indications. An autocomplete input field provides the ability to fetch a target
vector from existing Drugmonizome drug sets. Optionally, users can upload a
custom list of drugs with a common phenotype as the target binary target vector
for classification. Lastly, the Drugmonizome-ML Appyter machine learning
pipeline includes several scikit-learn (<xref rid="R42" ref-type="bibr">42</xref>) options for data normalization, dimensionality reduction,
feature selection, classification algorithms and methods to evaluate the
classifier. Once the input form is filled, a Jupyter Notebook is launched in the
cloud with all user-selected settings, a model is trained and then the trained
model is used to make predictions. After a job is completed, the results are
stored in the cloud and can be shared via a unique URL that provides access to
the executed Appyter notebook.</p>
    </sec>
    <sec id="s2-s6">
      <title>Predicting peripheral neuropathy as a side effect using
Drugmonizome-ML</title>
      <p>A set of 19 898 compounds with L1000 gene expression features for 978
landmark genes were downloaded and processed from SEP-L1000 (<xref rid="R32" ref-type="bibr">32</xref>), and Morgan chemical fingerprints
(radius = 4, nbits = 2048) were
computed for each compound with RDKit. The binary Morgan fingerprint features
were TF-IDF normalized to normalize for the frequency of different chemical
structures. Out of the 19 898 compounds present within the input dataset,
226 drugs known to have the side effect ‘peripheral neuropathy’
were identified within the SIDER side effects drug set library and used as the
positive class to make predictions for additional compounds that may cause this
side effect based on shared properties with the positive-label compounds. The
semantic mapping of small molecules between the SEP-L1000 and Drugmonizome drug
set libraries was performed by matching the complete InChIKeys. To optimize the
learning algorithm and hyperparameters, we used the scikit-learn Grid Search
with 10-fold cross-validation and evaluated the Logistic Regression, Support
Vector Machine, Extra Trees (ET) and Random Forest classifiers based on the Area
Under the Receiver Operating Characteristic Curve (AUROC) and Area Under the
Precision-Recall Curve (AUPRC) methods. Class weights were set to the inverse of
class frequency to handle the class imbalance present within the input dataset.
After model selection, we trained the best-performing ET model using 10-fold
stratified cross-validation with three repeats. We then examined the
validation-set predictions for each compound to identify additional compounds
that were not known to induce peripheral neuropathy before but received high
prediction scores.</p>
    </sec>
  </sec>
  <sec id="s3">
    <title>Results</title>
    <sec id="s3-s1">
      <title>Drugmonizome database</title>
      <p>In total, small molecule data from 13 unique resources were transformed into 35
drug set libraries with a total of 10 395 794
drug–attribute associations organized into 110 903 drug sets
spanning a variety of biomedical association terms (<xref rid="T1" ref-type="table">Table 1</xref>, <xref rid="F1" ref-type="fig">Figure 1</xref>).
14 579 unique drugs and small molecules from DrugBank (<xref rid="R17" ref-type="bibr">17</xref>) and the LINCS project (<xref rid="R21" ref-type="bibr">21</xref>) are included in the Drugmonizome
database. The Drugmonizome website includes a metadata search engine that
enables users to input any search term. The returned results include matching
drug sets, drugs, small molecules and other relevant entities. Information about
drugs and small molecules can be accessed from landing pages for each small
molecule or drug. These landing pages include a listing of all drug sets that
contain the small molecule. Information about each drug set includes drug set
size and the resource which the drug set was derived from. Additionally, the
user can explore which small molecules are included in each matching set. The
drug set enrichment analysis input form enables users to submit their own list
of small molecules for enrichment analysis (<xref rid="F2" ref-type="fig">Figure
2</xref>). Users can input small molecule lists by name, InChIKey, SMILES
string and resource-specific identifiers such as those from DrugBank or the
Broad Institute for LINCS small molecules IDs. A results page is generated for
each drug set library where drug sets from each library are ranked based on
overlap with the input drug set based on the Fisher’s exact test. The
results from each library can be further examined by looking at all metadata
associated with the enriched term. The drug set enrichment analysis can also be
accessed programmatically using the Drugmonizome documented OpenAPI (<xref rid="R43" ref-type="bibr">43</xref>). Drugmonizome also has a resources tab
that lists information about the 13 unique resources with links, PubMed IDs and
other identifying resource-level metadata.</p>
      <table-wrap position="float" id="T1">
        <label>Table 1.</label>
        <caption>
          <p>List of drug set libraries served by Drugmonizome</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th valign="bottom" colspan="1" align="left" rowspan="1">Resource</th>
              <th valign="bottom" colspan="1" align="left" rowspan="1">Dataset</th>
              <th valign="bottom" colspan="1" align="left" rowspan="1">Drugs</th>
              <th valign="bottom" colspan="1" align="left" rowspan="1">Attributes</th>
              <th valign="bottom" colspan="1" align="left" rowspan="1">Average drugs per
term</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Geneshot</td>
              <td rowspan="1" colspan="1">Tagger Predicted Genes</td>
              <td rowspan="1" colspan="1">3938</td>
              <td rowspan="1" colspan="1">13 882</td>
              <td rowspan="1" colspan="1">55.60</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Geneshot</td>
              <td rowspan="1" colspan="1">Enrichr Predicted Genes</td>
              <td rowspan="1" colspan="1">3938</td>
              <td rowspan="1" colspan="1">11 845</td>
              <td rowspan="1" colspan="1">62.03</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Geneshot</td>
              <td rowspan="1" colspan="1">AutoRIF Predicted Genes</td>
              <td rowspan="1" colspan="1">3938</td>
              <td rowspan="1" colspan="1">11 695</td>
              <td rowspan="1" colspan="1">66.03</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Geneshot</td>
              <td rowspan="1" colspan="1">GeneRIF Predicted Genes</td>
              <td rowspan="1" colspan="1">3938</td>
              <td rowspan="1" colspan="1">9193</td>
              <td rowspan="1" colspan="1">78.65</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Geneshot</td>
              <td rowspan="1" colspan="1">Coexpression Predicted Genes</td>
              <td rowspan="1" colspan="1">3938</td>
              <td rowspan="1" colspan="1">9087</td>
              <td rowspan="1" colspan="1">78.95</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">STITCH</td>
              <td rowspan="1" colspan="1">Targets_500</td>
              <td rowspan="1" colspan="1">7303</td>
              <td rowspan="1" colspan="1">9063</td>
              <td rowspan="1" colspan="1">89.05</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">L1000FWD</td>
              <td rowspan="1" colspan="1">Downregulated Genes</td>
              <td rowspan="1" colspan="1">4884</td>
              <td rowspan="1" colspan="1">7622</td>
              <td rowspan="1" colspan="1">139.10</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">L1000FWD</td>
              <td rowspan="1" colspan="1">Upregulated Genes</td>
              <td rowspan="1" colspan="1">4884</td>
              <td rowspan="1" colspan="1">7611</td>
              <td rowspan="1" colspan="1">142.88</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Geneshot</td>
              <td rowspan="1" colspan="1">Literature Associated Genes</td>
              <td rowspan="1" colspan="1">3938</td>
              <td rowspan="1" colspan="1">7503</td>
              <td rowspan="1" colspan="1">37.80</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">PharmGKB</td>
              <td rowspan="1" colspan="1">Predicted Side Effects</td>
              <td rowspan="1" colspan="1">1435</td>
              <td rowspan="1" colspan="1">7137</td>
              <td rowspan="1" colspan="1">70.72</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">CREEDS</td>
              <td rowspan="1" colspan="1">Upregulated Genes</td>
              <td rowspan="1" colspan="1">71</td>
              <td rowspan="1" colspan="1">2535</td>
              <td rowspan="1" colspan="1">11.67</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">CREEDS</td>
              <td rowspan="1" colspan="1">Downregulated Genes</td>
              <td rowspan="1" colspan="1">72</td>
              <td rowspan="1" colspan="1">2532</td>
              <td rowspan="1" colspan="1">11.76</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">SIDER</td>
              <td rowspan="1" colspan="1">Side Effects</td>
              <td rowspan="1" colspan="1">1635</td>
              <td rowspan="1" colspan="1">2078</td>
              <td rowspan="1" colspan="1">74.60</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">L1000FWD</td>
              <td rowspan="1" colspan="1">Upregulated GO Biological Processes</td>
              <td rowspan="1" colspan="1">4195</td>
              <td rowspan="1" colspan="1">1228</td>
              <td rowspan="1" colspan="1">58.03</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">L1000FWD</td>
              <td rowspan="1" colspan="1">Downregulated GO Biological Processes</td>
              <td rowspan="1" colspan="1">4013</td>
              <td rowspan="1" colspan="1">1068</td>
              <td rowspan="1" colspan="1">51.05</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">L1000FWD</td>
              <td rowspan="1" colspan="1">Predicted Side Effects</td>
              <td rowspan="1" colspan="1">4852</td>
              <td rowspan="1" colspan="1">1013</td>
              <td rowspan="1" colspan="1">99.34</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">SIDER</td>
              <td rowspan="1" colspan="1">Indications</td>
              <td rowspan="1" colspan="1">1546</td>
              <td rowspan="1" colspan="1">867</td>
              <td rowspan="1" colspan="1">21.66</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">PubChem</td>
              <td rowspan="1" colspan="1">PubChem Fingerprints</td>
              <td rowspan="1" colspan="1">13 379</td>
              <td rowspan="1" colspan="1">669</td>
              <td rowspan="1" colspan="1">2594.72</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">DrugBank</td>
              <td rowspan="1" colspan="1">Drug Targets</td>
              <td rowspan="1" colspan="1">4467</td>
              <td rowspan="1" colspan="1">611</td>
              <td rowspan="1" colspan="1">17.42</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">PharmGKB</td>
              <td rowspan="1" colspan="1">Single Nucleotide Polymorphisms</td>
              <td rowspan="1" colspan="1">483</td>
              <td rowspan="1" colspan="1">554</td>
              <td rowspan="1" colspan="1">10.02</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">DrugCentral</td>
              <td rowspan="1" colspan="1">Genes</td>
              <td rowspan="1" colspan="1">1555</td>
              <td rowspan="1" colspan="1">540</td>
              <td rowspan="1" colspan="1">19.16</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">DrugRepurposingHub</td>
              <td rowspan="1" colspan="1">Genes</td>
              <td rowspan="1" colspan="1">1720</td>
              <td rowspan="1" colspan="1">375</td>
              <td rowspan="1" colspan="1">15.57</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">ATC</td>
              <td rowspan="1" colspan="1">ATC Codes</td>
              <td rowspan="1" colspan="1">2233</td>
              <td rowspan="1" colspan="1">308</td>
              <td rowspan="1" colspan="1">9.91</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">KINOMEscan</td>
              <td rowspan="1" colspan="1">Kinases</td>
              <td rowspan="1" colspan="1">54</td>
              <td rowspan="1" colspan="1">301</td>
              <td rowspan="1" colspan="1">9.33</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">L1000FWD</td>
              <td rowspan="1" colspan="1">Upregulated KEGG Pathways</td>
              <td rowspan="1" colspan="1">3662</td>
              <td rowspan="1" colspan="1">245</td>
              <td rowspan="1" colspan="1">120.58</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">L1000FWD</td>
              <td rowspan="1" colspan="1">Downregulated KEGG Pathways</td>
              <td rowspan="1" colspan="1">3309</td>
              <td rowspan="1" colspan="1">236</td>
              <td rowspan="1" colspan="1">87.29</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">L1000FWD</td>
              <td rowspan="1" colspan="1">Upregulated GO Molecular Function</td>
              <td rowspan="1" colspan="1">2427</td>
              <td rowspan="1" colspan="1">183</td>
              <td rowspan="1" colspan="1">56.77</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">RDKit</td>
              <td rowspan="1" colspan="1">MACCS Fingerprints</td>
              <td rowspan="1" colspan="1">14 308</td>
              <td rowspan="1" colspan="1">163</td>
              <td rowspan="1" colspan="1">4080.18</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">L1000FWD</td>
              <td rowspan="1" colspan="1">Downregulated GO Molecular Function</td>
              <td rowspan="1" colspan="1">2158</td>
              <td rowspan="1" colspan="1">158</td>
              <td rowspan="1" colspan="1">48.56</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">L1000FWD</td>
              <td rowspan="1" colspan="1">Downregulated GO Cellular Component</td>
              <td rowspan="1" colspan="1">3246</td>
              <td rowspan="1" colspan="1">157</td>
              <td rowspan="1" colspan="1">100.82</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">DrugRepurposingHub</td>
              <td rowspan="1" colspan="1">Mechanisms of Action</td>
              <td rowspan="1" colspan="1">1854</td>
              <td rowspan="1" colspan="1">154</td>
              <td rowspan="1" colspan="1">13.37</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">L1000FWD</td>
              <td rowspan="1" colspan="1">Upregulated GO Cellular Component</td>
              <td rowspan="1" colspan="1">3366</td>
              <td rowspan="1" colspan="1">153</td>
              <td rowspan="1" colspan="1">101.87</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">DrugBank</td>
              <td rowspan="1" colspan="1">Enzymes</td>
              <td rowspan="1" colspan="1">1473</td>
              <td rowspan="1" colspan="1">72</td>
              <td rowspan="1" colspan="1">59.73</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">DrugBank</td>
              <td rowspan="1" colspan="1">Transporters</td>
              <td rowspan="1" colspan="1">832</td>
              <td rowspan="1" colspan="1">51</td>
              <td rowspan="1" colspan="1">46.80</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">DrugBank</td>
              <td rowspan="1" colspan="1">Carriers</td>
              <td rowspan="1" colspan="1">458</td>
              <td rowspan="1" colspan="1">14</td>
              <td rowspan="1" colspan="1">44.78</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <fig position="float" id="F1" fig-type="figure">
        <label>Figure 1.</label>
        <caption>
          <p>Counts of unique drug–term associations for each library. Terms
are colored by their term type groupings.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="baab017f1" position="float"/>
      </fig>
      <fig position="float" id="F2" fig-type="figure">
        <label>Figure 2.</label>
        <caption>
          <p>The Drugmonizome signature search workflow. A set of drugs is submitted
for enrichment analysis across all the Drugmonizome gene set libraries.
The enrichment results are provided in tables that enable further
exploration of the overlapping drugs.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="baab017f2" position="float"/>
      </fig>
    </sec>
    <sec id="s3-s2">
      <title>Drugmonizome COVID-19 case study</title>
      <p> In late 2019, the novel coronavirus, SARS-CoV-2, emerged in China and has since
claimed many lives and caused widespread economic disruption (<xref rid="R44" ref-type="bibr">44</xref>, <xref rid="R45" ref-type="bibr">45</xref>). Countless research groups in the scientific community refocused
their efforts toward discovering therapeutics for COVID-19. Given the immense
resources required for developing and testing novel small molecules, many groups
turned to drug repurposing—an alternative avenue for expedited discovery
of therapeutics with known safety profiles. The COVID-19 Drug and Gene Set
Library (<xref rid="R46" ref-type="bibr">46</xref>) was developed to collect
drug and gene sets related to COVID-19, including drug sets extracted from 12
publications that describe SARS-CoV-2 <italic toggle="yes">in vitro</italic> drug screens
(<xref rid="R47" ref-type="bibr">47–58</xref>). While there is not much overlap among the hits from
the 12 independent <italic toggle="yes">in vitro</italic> drug screens (<xref rid="F3" ref-type="fig">Figure 3</xref>), these drug sets share the common phenotype of
inhibiting SARS-CoV-2 infection in cell-based assays. Drugs and small molecules
were predominantly cataloged by name. Therefore, these entities could only be
resolved by their common name because identifiers were not supplied in most
cases (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table
S1</xref>). The drug sets from these <italic toggle="yes">in vitro</italic> screens were
independently submitted to Drugmonizome for enrichment analysis to highlight
potential common themes across the screening results. To determine commonalities
among the drug hits in perturbing the same biological processes, the top
enriched terms from the up- and downregulated L1000FWD GO Biological Processes
drug set libraries were collated. The top 20 terms across the enrichment results
were determined by the largest cumulative −log <italic toggle="yes">P</italic>-values,
and the contribution to the total by each drug screen was visualized as stacked
bar plots (<xref rid="F4" ref-type="fig">Figure 4</xref>). Notably, among the
pooled enrichment results for the 12 <italic toggle="yes">in vitro</italic> drug screens hits
there was a common theme of upregulated terms related to cholesterol metabolism,
including regulation of cholesterol metabolic process (GO:0090181), regulation
of cholesterol biosynthetic process (GO:0045540), sterol biosynthetic process
(GO:0016126) and cholesterol biosynthetic process (GO:0006695). It was recently
demonstrated that drugs that upregulate the genes related to cholesterol
biosynthesis can block SARS-CoV-2 in human cell lines and organoids (<xref rid="R59" ref-type="bibr">59</xref>).</p>
      <fig position="float" id="F3" fig-type="figure">
        <label>Figure 3.</label>
        <caption>
          <p>UpSet plot detailing the overlap among drug hits across 12 independent
published <italic toggle="yes">in</italic>
<italic toggle="yes">vitro</italic> drug screen studies.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="baab017f3" position="float"/>
      </fig>
      <fig position="float" id="F4" fig-type="figure">
        <label>Figure 4.</label>
        <caption>
          <p>Top 20 enriched GO Biological Processes terms for the 12
<italic toggle="yes">in</italic>
<italic toggle="yes">vitro</italic> SARS-CoV-2 drug screens. Enriched terms are
ranked by the sum of the −log(<italic toggle="yes">P</italic>-value) of the
term across all screens. The enriched terms are applied to the consensus
downregulated (A) and upregulated (B) genes for each drug in each set
based on the data provided from L1000FWD (<xref rid="R29" ref-type="bibr">29</xref>).</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="baab017f4" position="float"/>
      </fig>
    </sec>
    <sec id="s3-s3">
      <title>Drugmonizome ETL scripts, consensus analysis and machine learning
Appyters</title>
      <p>Appyters are bioinformatics web-based applications created from Jupyter Notebooks
(<xref rid="R39" ref-type="bibr">39</xref>). By placing special code inside
a standard Jupyter Notebook, and compiling the notebook with the Appyter SDK,
the notebook is converted into a fully functional web application. The Appyter
web-based application first presents the user with an input form, where they can
upload files and submit input parameters. When submitted, the Jupyter Notebook
is executed in the cloud and a report is generated and presented to the user.
Users are also provided with a permanent link to the executed notebook, options
to download the notebook, download the output from the notebook and apply
further customization to the results. The Appyters Catalog provides a collection
of Appyters developed by the community. The Drugmonizome extracting,
transforming and loading (ETL) Appyters are a collection of Appyters that
convert data from various online resources that provide knowledge about drugs
and small molecules into drug set libraries for Drugmonizome. Hence, several
Appyters for ETL data from each resource in Drugmonizome were created for the
purpose of automating the process of updating all drug set libraries. The
Jupyter Notebooks used to create these Appyters are openly shared and versioned
on GitHub. This approach provides simple mechanisms to continually update the
Drugmonizome resource. The Drugmonizome Consensus Appyter streamlines the
analysis of a collection of drug sets. After uploading a file containing drug
sets, users can select the Drugmonizome drug set libraries for enrichment
analysis, as well as how many top consensus terms to visualize. When executed,
the Appyter produces a report that contains a stacked bar chart with the
cumulative ranks of enriched terms from each library. An example is the chart
provided for the SARS-CoV-2 <italic toggle="yes">in vitro</italic> drug screens case study
(<xref rid="F4" ref-type="fig">Figure 4</xref>). The Appyter also produces
downloadable tables and heatmaps.</p>
    </sec>
    <sec id="s3-s4">
      <title>Drugmonizome-ML Appyter and the peripheral neuropathy case study</title>
      <p>The Drugmonizome-ML Appyter is a customizable machine learning pipeline that is
available as an Appyter. Using an HTML input form, Drugmonizome-ML enables users
to choose feature matrices and target vectors to construct machine learning
tasks for predicting drug attributes. The user has the option to choose from
various scikit-learn (<xref rid="R42" ref-type="bibr">42</xref>) settings to
customize and evaluate a user-selected classifier algorithm. As a case study, we
trained a classifier to identify preclinical and approved drugs that may cause
peripheral neuropathy as a side effect. Peripheral neuropathy is a debilitating
side effect for many drugs, common among chemotherapeutics (<xref rid="R60" ref-type="bibr">60</xref>). It causes loss of sensation or pain in
the hands and feet, as well as overall weakness and pain. Peripheral neuropathy
is also a side effect of diabetes (<xref rid="R61" ref-type="bibr">61</xref>).
Since many critical side effects may be missed during clinical trials,
computationally predicting side effects such as peripheral neuropathy for new
drug applications can alert physicians about potential side effects to watch for
during clinical trials. A collection of 19 898 compounds characterized by
their effects on gene expression and their chemical fingerprint features were
used to train and evaluate a classifier that can predict associations between
compounds and peripheral neuropathy. The input dataset for constructing the
classifier consisted of L1000 gene expression signatures of 978 landmark genes
after perturbation with each compound (<xref rid="R32" ref-type="bibr">32</xref>, <xref rid="R40" ref-type="bibr">40</xref>) and Morgan fingerprints
(radius = 4, nbits = 2048) generated
with RDKit (<xref rid="R37" ref-type="bibr">37</xref>). Compounds known to cause
peripheral neuropathy were curated from SIDER (<xref rid="R31" ref-type="bibr">31</xref>). We evaluated various classifier algorithms after hyperparameter
optimization based on AUROC and AUPRC (<xref rid="F5" ref-type="fig">Figure
5</xref>). Based on this analysis, we selected the ET classier due to its
short training time and marginally better AUPRC. We trained an ET classifier
(n_estimators = 1250,
class_weight = balanced,
max_features = log2,
criterion = entropy) with 10-fold cross-validation repeated
three times to predict novel compounds that may cause peripheral neuropathy as a
side effect. The top-ranked predicted compounds are ranked by their mean
prediction probabilities (<xref rid="T2 T3" ref-type="table">Tables 2 and
3</xref>).</p>
      <fig position="float" id="F5" fig-type="figure">
        <label>Figure 5.</label>
        <caption>
          <p>Drugmonizome-ML classifier for prioritizing drugs that may induce
peripheral neuropathy. (A) Input feature space with Uniform Manifold
Approximation and Projection (UMAP) dimensionality reduction. Each point
represents one of 19 898 compounds with 3026 features per
compound. Compounds with the known side effect of peripheral neuropathy
are highlighted in yellow. (B) ROC and (C) PRC across cross-validation
splits after hyperparameter optimization for each classifier to predict
peripheral neuropathy. Each curve shows the mean ROC and standard
deviation after 10-fold cross-validation for each classifier.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="baab017f5" position="float"/>
      </fig>
      <table-wrap position="float" id="T2">
        <label>Table 2.</label>
        <caption>
          <p>Top 15 drugs predicted by the ET model that are known to be associated
with peripheral neuropathy from SIDER</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th valign="bottom" align="left" rowspan="1" colspan="1">InChIKey</th>
              <th valign="bottom" align="left" rowspan="1" colspan="1">Name</th>
              <th valign="bottom" align="left" rowspan="1" colspan="1">Known</th>
              <th valign="bottom" align="left" rowspan="1" colspan="1">Prediction probability</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">JURKNVYFZMSNLP-UHFFFAOYSA-N</td>
              <td rowspan="1" colspan="1">Cyclobenzaprine (BRD-K42348709)</td>
              <td rowspan="1" colspan="1">TRUE</td>
              <td rowspan="1" colspan="1">0.8592</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">KRMDCWKBEZIMAB-UHFFFAOYSA-N</td>
              <td rowspan="1" colspan="1">Amitriptyline (BRD-K53737926)</td>
              <td rowspan="1" colspan="1">TRUE</td>
              <td rowspan="1" colspan="1">0.8311</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">MJIHNNLFOKEZEW-UHFFFAOYSA-N</td>
              <td rowspan="1" colspan="1">Lansoprazole (BRD-A49172652)</td>
              <td rowspan="1" colspan="1">TRUE</td>
              <td rowspan="1" colspan="1">0.7613</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">ZZVUWRFHKOJYTH-UHFFFAOYSA-N</td>
              <td rowspan="1" colspan="1">Diphenhydramine (BRD-K47278471)</td>
              <td rowspan="1" colspan="1">TRUE</td>
              <td rowspan="1" colspan="1">0.7153</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">ZKMNUMMKYBVTFN-HNNXBMFYSA-N</td>
              <td rowspan="1" colspan="1">Ropivacaine (BRD-K50938786)</td>
              <td rowspan="1" colspan="1">TRUE</td>
              <td rowspan="1" colspan="1">0.582</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">BCGWQEUPMDMJNV-UHFFFAOYSA-N</td>
              <td rowspan="1" colspan="1">Imipramine (BRD-K38436528)</td>
              <td rowspan="1" colspan="1">TRUE</td>
              <td rowspan="1" colspan="1">0.5591</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">WUBBRNOQWQTFEX-UHFFFAOYSA-N</td>
              <td rowspan="1" colspan="1">Aminosalicylic acid (BRD-K80267133)</td>
              <td rowspan="1" colspan="1">TRUE</td>
              <td rowspan="1" colspan="1">0.4977</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">YREYEVIYCVEVJK-UHFFFAOYSA-N</td>
              <td rowspan="1" colspan="1">Rabeprazole (BRD-A39390670)</td>
              <td rowspan="1" colspan="1">TRUE</td>
              <td rowspan="1" colspan="1">0.457</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">PHTUQLWOUWZIMZ-GZTJUZNOSA-N</td>
              <td rowspan="1" colspan="1">Dosulepin (BRD-K54759182)</td>
              <td rowspan="1" colspan="1">TRUE</td>
              <td rowspan="1" colspan="1">0.3622</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">XRECTZIEBJDKEO-UHFFFAOYSA-N</td>
              <td rowspan="1" colspan="1">Flucytosine (BRD-K82143716)</td>
              <td rowspan="1" colspan="1">TRUE</td>
              <td rowspan="1" colspan="1">0.3463</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">ODQWQRRAPPTVAG-BOPFTXTBSA-N</td>
              <td rowspan="1" colspan="1">Doxepin (BRD-K37694030)</td>
              <td rowspan="1" colspan="1">TRUE</td>
              <td rowspan="1" colspan="1">0.3403</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">UGJMXCAKCUNAIE-UHFFFAOYSA-N</td>
              <td rowspan="1" colspan="1">Gabapentin (BRD-K62737565)</td>
              <td rowspan="1" colspan="1">TRUE</td>
              <td rowspan="1" colspan="1">0.333</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">KBOPZPXVLCULAV-UHFFFAOYSA-N</td>
              <td rowspan="1" colspan="1">Mesalazine (BRD-K28849549)</td>
              <td rowspan="1" colspan="1">TRUE</td>
              <td rowspan="1" colspan="1">0.3244</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">GBXSMTUPTTWBMN-XIRDDKMYSA-N</td>
              <td rowspan="1" colspan="1">Enalapril (BRD-K57545991)</td>
              <td rowspan="1" colspan="1">TRUE</td>
              <td rowspan="1" colspan="1">0.3153</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">HCYAFALTSJYZDH-UHFFFAOYSA-N</td>
              <td rowspan="1" colspan="1">Desipramine (BRD-K60762818)</td>
              <td rowspan="1" colspan="1">TRUE</td>
              <td rowspan="1" colspan="1">0.3102</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <table-wrap position="float" id="T3">
        <label>Table 3.</label>
        <caption>
          <p>Top 15 drugs predicted by the ET model that are unknown to be associated
with peripheral neuropathy</p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="left" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th valign="bottom" align="left" rowspan="1" colspan="1">InChIKey</th>
              <th valign="bottom" align="left" rowspan="1" colspan="1">Name</th>
              <th valign="bottom" align="left" rowspan="1" colspan="1">Known</th>
              <th valign="bottom" align="left" rowspan="1" colspan="1">Prediction probability</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">NRUKOCRGYNPUPR-OQMCATNJSA-N</td>
              <td rowspan="1" colspan="1">PLX-4720 (BRD-K16478699)</td>
              <td rowspan="1" colspan="1">FALSE</td>
              <td rowspan="1" colspan="1">0.9757</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">NRUKOCRGYNPUPR-OQMCATNJSA-N</td>
              <td rowspan="1" colspan="1">Teniposide (BRD-A35588707)</td>
              <td rowspan="1" colspan="1">FALSE</td>
              <td rowspan="1" colspan="1">0.9396</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">STQGQHZAVUOBTE-INJOJONLSA-N</td>
              <td rowspan="1" colspan="1">Daunorubicin (BRD-K91966436)</td>
              <td rowspan="1" colspan="1">FALSE</td>
              <td rowspan="1" colspan="1">0.8372</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">VSJKWCGYPAHWDS-FQEVSTJZSA-N</td>
              <td rowspan="1" colspan="1">Camptothecin (BRD-K37890730)</td>
              <td rowspan="1" colspan="1">FALSE</td>
              <td rowspan="1" colspan="1">0.7782</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">FPIPGXGPPPQFEQ-OVSJKPMPSA-N</td>
              <td rowspan="1" colspan="1">Retinol (BRD-K22429181)</td>
              <td rowspan="1" colspan="1">FALSE</td>
              <td rowspan="1" colspan="1">0.7499</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">LTMKESNXUBQKBP-UHFFFAOYSA-N</td>
              <td rowspan="1" colspan="1">Lapatinib (BRD-M07438658)</td>
              <td rowspan="1" colspan="1">FALSE</td>
              <td rowspan="1" colspan="1">0.7442</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">HHJUWIANJFBDHT-KOTLKJBCSA-N</td>
              <td rowspan="1" colspan="1">Vindesine (BRD-K59753975)</td>
              <td rowspan="1" colspan="1">FALSE</td>
              <td rowspan="1" colspan="1">0.7429</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">XECQQDXTQRYYBH-UHFFFAOYSA-N</td>
              <td rowspan="1" colspan="1">Norcyclobenzaprine (BRD-K63165456)</td>
              <td rowspan="1" colspan="1">FALSE</td>
              <td rowspan="1" colspan="1">0.6919</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">FPIPGXGPPPQFEQ-UHFFFAOYSA-N</td>
              <td rowspan="1" colspan="1">Tretinoin (BRD-K64634304)</td>
              <td rowspan="1" colspan="1">FALSE</td>
              <td rowspan="1" colspan="1">0.6753</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">XUBOMFCQGDBHNK-UHFFFAOYSA-N</td>
              <td rowspan="1" colspan="1">Gatifloxacin (BRD-A74980173)</td>
              <td rowspan="1" colspan="1">FALSE</td>
              <td rowspan="1" colspan="1">0.6338</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">AJLFOPYRIVGYMJ-INTXDZFKSA-N</td>
              <td rowspan="1" colspan="1">Mevastatin (BRD-K94441233)</td>
              <td rowspan="1" colspan="1">FALSE</td>
              <td rowspan="1" colspan="1">0.6235</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">KPQZUUQMTUIKBP-UHFFFAOYSA-N</td>
              <td rowspan="1" colspan="1">Secnidazole (BRD-A70083328)</td>
              <td rowspan="1" colspan="1">FALSE</td>
              <td rowspan="1" colspan="1">0.5208</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">METKIMKYRPQLGS-LBPRGKRZSA-N</td>
              <td rowspan="1" colspan="1">Atenolol (BRD-K44993696)</td>
              <td rowspan="1" colspan="1">FALSE</td>
              <td rowspan="1" colspan="1">0.4875</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">KGUMXGDKXYTTEY-FRCNGJHJSA-N</td>
              <td rowspan="1" colspan="1">4-Hydroxyretinoic acid (BRD-A96799240)</td>
              <td rowspan="1" colspan="1">FALSE</td>
              <td rowspan="1" colspan="1">0.4861</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">BUJAGSGYPOAWEI-UHFFFAOYSA-N</td>
              <td rowspan="1" colspan="1">Tocainide (BRD-A92670106)</td>
              <td rowspan="1" colspan="1">FALSE</td>
              <td rowspan="1" colspan="1">0.4753</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
  </sec>
  <sec id="s4">
    <title>Discussion</title>
    <p>The ability to perform drug set enrichment analyses for sets of small molecules
against drug set libraries curated from public repositories and biomedical
literature using the Drugmonizome web-based interface can shed light on the
connectedness of sets of small molecule hits generated from drug screens. The
COVID-19 case study highlighted a global theme that connects results from 12
independent <italic toggle="yes">in</italic>
<italic toggle="yes">vitro</italic> drug screens. Despite the minimal overlap among the hits
across these screens, GO terms related to regulation of cholesterol metabolism and
cell cycle were significantly enriched across the 12 independent drug sets. It
should be noted that the cholesterol biosynthesis metabolic pathway is not just
producing cholesterol, it is known to produce more than 300 metabolites. A few of
these are likely critical to the virus life cycle. It has been reported that
patients with high cholesterol and hypertension are at a higher risk of developing
COVID-19 (<xref rid="R62" ref-type="bibr">62</xref>), and previous literature
reports that cholesterol has important functions in regulating immune function,
namely through alteration of plasma membrane cholesterol content, which may have
effects on viral entry into cells (<xref rid="R63" ref-type="bibr">63</xref>, <xref rid="R64" ref-type="bibr">64</xref>). Furthermore, several independent studies
suggest that statins, which are cholesterol-lowering drugs, may reduce the severity
of COVID-19 (<xref rid="R65" ref-type="bibr">65–68</xref>). While
this evidence appears as a contradiction, lowering vs. increasing the level of
cholesterol, it may be because the drugs that block the virus <italic toggle="yes">in
vitro</italic> simply induce the expression of the cholesterol biosynthesis
pathway and do not necessarily increase the production of cholesterol. Specifically,
these drugs collectively upregulate the genes belonging to this pathway, while it
was shown that the virus downregulates the same genes (<xref rid="R59" ref-type="bibr">59</xref>). Further understanding the exact metabolites that lead to
increase or attenuation of infection requires further exploration. It should be
noted that the drug sets used for this case study come from the COVID-19 Drug and
Gene Set Library (<xref rid="R46" ref-type="bibr">46</xref>). This site provides
links to drug set enrichment analysis with DrugEnrichr (<xref rid="R69" ref-type="bibr">69</xref>) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://maayanlab.cloud/DrugEnrichr/" ext-link-type="uri">https://maayanlab.cloud/DrugEnrichr/</ext-link>). DrugEnrichr was developed by
us to provide drug set enrichment analysis using the same drug set libraries created
for Drugmonizome. This was achieved by simply swapping the Enrichr gene set
libraries with the Drugmonizome drug set libraries. DrugEnrichr has fewer features
when compared with Drugmonizome, for example, it does not have entity resolution,
drug landing pages and extensive metadata search. The underlying database and
enrichment analysis calculation in Drugmonizome and DrugEnrichr are identical.
Hence, users may prefer the simpler user interface provided by DrugEnrichr. However,
we recommend using Drugmonizome over DrugEnrichr.</p>
    <p>For our second case study, we utilized the Drugmonizome-ML Appyter to make
predictions and impute knowledge. Drugmonizome-ML provides researchers with the
ability to construct custom machine learning pipelines using a simple input form. We
used Drugmonizome-ML to predict peripheral neuropathy as a side effect for
∼20 000 preclinical and approved compounds. Among the top-ranked
compounds that were not known to induce peripheral neuropathy from our input dataset
were PLX-4720, a BRAF kinase inhibitor (<xref rid="R70" ref-type="bibr">70</xref>);
camptothecin, a topoisomerase inhibitor (<xref rid="R71" ref-type="bibr">71</xref>);
vindesine, a vinblastine derivative antineoplastic (<xref rid="R72" ref-type="bibr">72</xref>); and various forms of retinol, a fat-soluble vitamin (<xref rid="R73" ref-type="bibr">73</xref>). Additionally, stereoisomers of compounds
known to induce peripheral neuropathy such as lapatinib, teniposide and daunorubicin
were ranked as the top predicted compounds when left out as positives from the
target prediction vector. This case study provides further evidence that
Drugmonizome-ML can be used to prioritize compounds that induce peripheral
neuropathy based on their transcriptomic profiles and chemical fingerprints. The top
predicted compounds were predominantly chemotherapeutics that are enzyme inhibitors.
It is well established that peripheral neuropathy is a common side effect among many
therapeutics for cancer. Because clinical trials cannot capture all possible adverse
effects of a therapeutic, computationally predicting compounds that may have severe
side effects before they reach the market is vital for preventing unwanted
consequences of treatment for patients. Beyond predicting side effects,
Drugmonizome-ML provides the ability to predict other drug attributes. In fact, any
attribute from the Drugmonizome drug set libraries such as indications, targets and
others can be set up for constructing machine learning predictive models.
Drugmonizome-ML targets researchers with no coding skills, but it is also expected
to be useful for computationally savvy users that would utilize the Drugmonizome-ML
framework as a skeleton for rapidly developing their ML models. It should be noted
that the data within the Drugmonizome database is highly abstracted. This results in
loss of information that may be critical to obtain optimal predictions. Regardless
of such limitations, Drugmonizome and Drugmonizome-ML provide rich and
well-organized knowledge about drugs and small molecules to facilitate and
accelerate early-stage drug discovery efforts.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>baab017_Supp</label>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="baab017_Supp.zip">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <sec id="s5">
    <title>Supplementary data</title>
    <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> are
available at <italic toggle="yes">Database</italic> Online.</p>
  </sec>
  <sec id="s6">
    <title>Funding</title>
    <p>National Institutes of Health (U24CA224260, U54HL127624, OT2OD030160).</p>
  </sec>
  <sec sec-type="data-availability" id="s7">
    <title>Data availability</title>
    <p>The Drugmonizome web site:</p>
    <p>
      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://maayanlab.cloud/drugmonizome" ext-link-type="uri">https://maayanlab.cloud/drugmonizome</ext-link>
    </p>
    <p>The Drugmonizome-ML Appyter:</p>
    <p>
      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://appyters.maayanlab.cloud/#/Drugmonizome_ML" ext-link-type="uri">https://appyters.maayanlab.cloud/#/Drugmonizome_ML</ext-link>
    </p>
    <p>The Drugmonizome ETL Appyters:</p>
    <p>
      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://appyters.maayanlab.cloud/#/?q=ETL%20&amp;tags=Drugmonizome" ext-link-type="uri">https://appyters.maayanlab.cloud/#/?q=ETL%20&amp;tags=Drugmonizome</ext-link>
    </p>
    <p>The Drugmonizome Consensus Appyter:</p>
    <p>
      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://appyters.maayanlab.cloud/#/Drugmonizome_Consensus_Terms" ext-link-type="uri">https://appyters.maayanlab.cloud/#/Drugmonizome_Consensus_Terms</ext-link>
    </p>
    <p>Source code for the drug set library processing scripts:</p>
    <p>
      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/MaayanLab/Drugmonizome" ext-link-type="uri">https://github.com/MaayanLab/Drugmonizome</ext-link>
    </p>
    <p>Source code for the ETL Appyters:</p>
    <p>
      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/MaayanLab/Drugmonizome-Data-Processing-Appyters" ext-link-type="uri">https://github.com/MaayanLab/Drugmonizome-Data-Processing-Appyters</ext-link>
    </p>
    <p>Source code for the Drugmonizome Consensus Appyter:</p>
    <p>
      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/MaayanLab/appyter-catalog/tree/master/appyters/Drugmonizome_Consensus_Terms" ext-link-type="uri">https://github.com/MaayanLab/appyter-catalog/tree/master/appyters/Drugmonizome_Consensus_Terms</ext-link>
    </p>
    <p>Source code for the Drugmonizome-ML Appyter:</p>
    <p>
      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/MaayanLab/Drugmonizome-ML" ext-link-type="uri">https://github.com/MaayanLab/Drugmonizome-ML</ext-link>
    </p>
  </sec>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="R1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scannell</surname><given-names>J.W.</given-names></string-name>,
<string-name><surname>Blanckley</surname><given-names>A.</given-names></string-name>,
<string-name><surname>Boldon</surname><given-names>H.</given-names></string-name></person-group><etal>et al.</etal> (<year>2012</year>) <article-title>Diagnosing the decline in
pharmaceutical R&amp;D efficiency</article-title>. <source><italic toggle="yes">Nat. Rev.
Drug Discov.</italic></source>, <volume>11</volume>,
<fpage>191</fpage>–<lpage>200</lpage>.<pub-id pub-id-type="pmid">22378269</pub-id></mixed-citation>
    </ref>
    <ref id="R2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Waring</surname><given-names>M.J.</given-names></string-name>,
<string-name><surname>Arrowsmith</surname><given-names>J.</given-names></string-name>,
<string-name><surname>Leach</surname><given-names>A.R.</given-names></string-name></person-group><etal>et al.</etal> (<year>2015</year>) <article-title>An analysis of the
attrition of drug candidates from four major pharmaceutical
companies</article-title>. <source><italic toggle="yes">Nat. Rev. Drug
Discov.</italic></source>, <volume>14</volume>,
<fpage>475</fpage>–<lpage>486</lpage>.<pub-id pub-id-type="pmid">26091267</pub-id></mixed-citation>
    </ref>
    <ref id="R3">
      <label>3.</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Brown</surname><given-names>N.</given-names></string-name>,
<string-name><surname>Cambruzzi</surname><given-names>J.</given-names></string-name>,
<string-name><surname>Cox</surname><given-names>P.J.</given-names></string-name></person-group><etal>et al.</etal> (<year>2018</year>) <chapter-title>Big data in drug
discovery</chapter-title>. In: <source><italic toggle="yes">Progress in Medicinal
Chemistry</italic></source>. Vol. <volume>57</volume>.
<publisher-loc>Elsevier BV Amsterdam</publisher-loc>,
<publisher-name>Netherlands</publisher-name>, pp.
<fpage>277</fpage>–<lpage>356</lpage>.<pub-id pub-id-type="pmid">29680150</pub-id></mixed-citation>
    </ref>
    <ref id="R4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Qian</surname><given-names>T.</given-names></string-name>,
<string-name><surname>Zhu</surname><given-names>S.</given-names></string-name>
and
<string-name><surname>Hoshida</surname><given-names>Y.</given-names></string-name></person-group>
(<year>2019</year>) <article-title>Use of big data in drug development for
precision medicine: an update</article-title>. <source><italic toggle="yes">Expert Rev.
Precis. Med. Drug Dev.</italic></source>, <volume>4</volume>,
<fpage>189</fpage>–<lpage>200</lpage>.<pub-id pub-id-type="pmid">31286058</pub-id></mixed-citation>
    </ref>
    <ref id="R5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pushpakom</surname><given-names>S.</given-names></string-name>,
<string-name><surname>Iorio</surname><given-names>F.</given-names></string-name>,
<string-name><surname>Eyers</surname><given-names>P.A.</given-names></string-name></person-group><etal>et al.</etal> (<year>2019</year>) <article-title>Drug repurposing:
progress, challenges and recommendations</article-title>.
<source><italic toggle="yes">Nat. Rev. Drug Discov.</italic></source>,
<volume>18</volume>,
<fpage>41</fpage>–<lpage>58</lpage>.<pub-id pub-id-type="pmid">30310233</pub-id></mixed-citation>
    </ref>
    <ref id="R6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ashburn</surname><given-names>T.T.</given-names></string-name>
and
<string-name><surname>Thor</surname><given-names>K.B.</given-names></string-name></person-group>
(<year>2004</year>) <article-title>Drug repositioning: identifying and
developing new uses for existing drugs</article-title>. <source><italic toggle="yes">Nat.
Rev. Drug Discov.</italic></source>, <volume>3</volume>,
<fpage>673</fpage>–<lpage>683</lpage>.<pub-id pub-id-type="pmid">15286734</pub-id></mixed-citation>
    </ref>
    <ref id="R7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Subramanian</surname><given-names>A.</given-names></string-name>,
<string-name><surname>Tamayo</surname><given-names>P.</given-names></string-name>,
<string-name><surname>Mootha</surname><given-names>V.K.</given-names></string-name></person-group><etal>et al.</etal> (<year>2005</year>) <article-title>Gene set enrichment
analysis: a knowledge-based approach for interpreting genome-wide expression
profiles</article-title>. <source><italic toggle="yes">Proc. Natl. Acad. Sci.
U.S.A.</italic></source>, <volume>102</volume>,
<fpage>15545</fpage>–<lpage>15550</lpage>.<pub-id pub-id-type="pmid">16199517</pub-id></mixed-citation>
    </ref>
    <ref id="R8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>E.Y.</given-names></string-name>,
<string-name><surname>Tan</surname><given-names>C.M.</given-names></string-name>,
<string-name><surname>Kou</surname><given-names>Y.</given-names></string-name></person-group><etal>et al.</etal> (<year>2013</year>) <article-title>Enrichr: interactive and
collaborative HTML5 gene list enrichment analysis tool</article-title>.
<source><italic toggle="yes">BMC Bioinform.</italic></source>, <volume>14</volume>,
<page-range>128</page-range>.</mixed-citation>
    </ref>
    <ref id="R9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kuleshov</surname><given-names>M.V.</given-names></string-name>,
<string-name><surname>Jones</surname><given-names>M.R.</given-names></string-name>,
<string-name><surname>Rouillard</surname><given-names>A.D.</given-names></string-name></person-group><etal>et al.</etal> (<year>2016</year>) <article-title>Enrichr: a comprehensive
gene set enrichment analysis web server 2016 update</article-title>.
<source><italic toggle="yes">Nucleic Acids Res.</italic></source>,
<volume>44</volume>,
<fpage>W90</fpage>–<lpage>W97</lpage>.<pub-id pub-id-type="pmid">27141961</pub-id></mixed-citation>
    </ref>
    <ref id="R10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liao</surname><given-names>Y.</given-names></string-name>,
<string-name><surname>Wang</surname><given-names>J.</given-names></string-name>,
<string-name><surname>Jaehnig</surname><given-names>E.J.</given-names></string-name></person-group><etal>et al.</etal> (<year>2019</year>) <article-title>WebGestalt 2019: gene set
analysis toolkit with revamped UIs and APIs</article-title>.
<source><italic toggle="yes">Nucleic Acids Res.</italic></source>,
<volume>47</volume>,
<fpage>W199</fpage>–<lpage>W205</lpage>.<pub-id pub-id-type="pmid">31114916</pub-id></mixed-citation>
    </ref>
    <ref id="R11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sherman</surname><given-names>B.T.</given-names></string-name>
and
<string-name><surname>Lempicki</surname><given-names>R.A.</given-names></string-name></person-group>
(<year>2009</year>) <article-title>Systematic and integrative analysis of
large gene lists using DAVID bioinformatics resources</article-title>.
<source><italic toggle="yes">Nat. Protoc.</italic></source>, <volume>4</volume>,
<fpage>44</fpage>–<lpage>57</lpage>.<pub-id pub-id-type="pmid">19131956</pub-id></mixed-citation>
    </ref>
    <ref id="R12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Napolitano</surname><given-names>F.</given-names></string-name>,
<string-name><surname>Sirci</surname><given-names>F.</given-names></string-name>,
<string-name><surname>Carrella</surname><given-names>D.</given-names></string-name></person-group><etal>et al.</etal> (<year>2016</year>) <article-title>Drug-set enrichment
analysis: a novel tool to investigate drug mode of action</article-title>.
<source><italic toggle="yes">Bioinformatics</italic></source>, <volume>32</volume>,
<fpage>235</fpage>–<lpage>241</lpage>.<pub-id pub-id-type="pmid">26415724</pub-id></mixed-citation>
    </ref>
    <ref id="R13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname><given-names>C.</given-names></string-name>,
<string-name><surname>Yang</surname><given-names>W.</given-names></string-name>,
<string-name><surname>Wang</surname><given-names>J.</given-names></string-name></person-group><etal>et al.</etal> (<year>2018</year>) <article-title>The DrugPattern tool for
drug set enrichment analysis and its prediction for beneficial effects of
oxLDL on type 2 diabetes</article-title>. <source><italic toggle="yes">J. Genet.
Genomics</italic></source>, <volume>45</volume>,
<fpage>389</fpage>–<lpage>397</lpage>.<pub-id pub-id-type="pmid">30054214</pub-id></mixed-citation>
    </ref>
    <ref id="R14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saitwal</surname><given-names>H.</given-names></string-name>,
<string-name><surname>Qing</surname><given-names>D.</given-names></string-name>,
<string-name><surname>Jones</surname><given-names>S.</given-names></string-name></person-group><etal>et al.</etal> (<year>2012</year>) <article-title>Cross-terminology mapping
challenges: a demonstration using medication terminological
systems</article-title>. <source><italic toggle="yes">J. Biomed.
Inform.</italic></source>, <volume>45</volume>,
<fpage>613</fpage>–<lpage>625</lpage>.<pub-id pub-id-type="pmid">22750536</pub-id></mixed-citation>
    </ref>
    <ref id="R15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kuhn</surname><given-names>M.</given-names></string-name>,
<string-name><surname>Szklarczyk</surname><given-names>D.</given-names></string-name>,
<string-name><surname>Franceschini</surname><given-names>A.</given-names></string-name></person-group><etal>et al.</etal> (<year>2010</year>) <article-title>STITCH 2: an interaction
network database for small molecules and proteins</article-title>.
<source><italic toggle="yes">Nucleic Acids Res.</italic></source>,
<volume>38</volume>,
<fpage>D552</fpage>–<lpage>D556</lpage>.<pub-id pub-id-type="pmid">19897548</pub-id></mixed-citation>
    </ref>
    <ref id="R16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chambers</surname><given-names>J.</given-names></string-name>,
<string-name><surname>Davies</surname><given-names>M.</given-names></string-name>,
<string-name><surname>Gaulton</surname><given-names>A.</given-names></string-name></person-group><etal>et al.</etal> (<year>2014</year>) <article-title>UniChem: extension of
InChI-based compound mapping to salt, connectivity and stereochemistry
layers</article-title>. <source><italic toggle="yes">J. Cheminform.</italic></source>,
<volume>6</volume>, <page-range>43</page-range>,
<fpage>1</fpage>–<lpage>10</lpage>.<pub-id pub-id-type="pmid">24397863</pub-id></mixed-citation>
    </ref>
    <ref id="R17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wishart</surname><given-names>D.S.</given-names></string-name>,
<string-name><surname>Feunang</surname><given-names>Y.D.</given-names></string-name>,
<string-name><surname>Guo</surname><given-names>A.C.</given-names></string-name></person-group><etal>et al.</etal> (<year>2018</year>) <article-title>DrugBank 5.0: a major
update to the DrugBank database for 2018</article-title>.
<source><italic toggle="yes">Nucleic Acids Res.</italic></source>,
<volume>46</volume>,
<fpage>D1074</fpage>–<lpage>D1082</lpage>.<pub-id pub-id-type="pmid">29126136</pub-id></mixed-citation>
    </ref>
    <ref id="R18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Himmelstein</surname><given-names>D.S.</given-names></string-name>,
<string-name><surname>Lizee</surname><given-names>A.</given-names></string-name>,
<string-name><surname>Hessler</surname><given-names>C.</given-names></string-name></person-group><etal>et al.</etal> (<year>2017</year>) <article-title>Systematic integration of
biomedical knowledge prioritizes drugs for repurposing</article-title>.
<source><italic toggle="yes">Elife</italic></source>, <volume>6</volume>,
<page-range>e26726</page-range>.</mixed-citation>
    </ref>
    <ref id="R19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname><given-names>S.</given-names></string-name>,
<string-name><surname>Thiessen</surname><given-names>P.A.</given-names></string-name>,
<string-name><surname>Bolton</surname><given-names>E.E.</given-names></string-name></person-group><etal>et al.</etal> (<year>2016</year>) <article-title>PubChem substance and
compound databases</article-title>. <source><italic toggle="yes">Nucleic Acids
Res.</italic></source>, <volume>44</volume>,
<fpage>D1202</fpage>–<lpage>D1213</lpage>.<pub-id pub-id-type="pmid">26400175</pub-id></mixed-citation>
    </ref>
    <ref id="R20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hewett</surname><given-names>M.</given-names></string-name>,
<string-name><surname>Oliver</surname><given-names>D.E.</given-names></string-name>,
<string-name><surname>Rubin</surname><given-names>D.L.</given-names></string-name></person-group><etal>et al.</etal> (<year>2002</year>) <article-title>PharmGKB: the
pharmacogenetics knowledge base</article-title>. <source><italic toggle="yes">Nucleic
Acids Res.</italic></source>, <volume>30</volume>,
<fpage>163</fpage>–<lpage>165</lpage>.<pub-id pub-id-type="pmid">11752281</pub-id></mixed-citation>
    </ref>
    <ref id="R21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Keenan</surname><given-names>A.B.</given-names></string-name>,
<string-name><surname>Jenkins</surname><given-names>S.L.</given-names></string-name>,
<string-name><surname>Jagodnik</surname><given-names>K.M.</given-names></string-name></person-group><etal>et al.</etal> (<year>2018</year>) <article-title>The library of integrated
network-based cellular signatures NIH program: system-level cataloging of
human cells response to perturbations</article-title>. <source><italic toggle="yes">Cell
Systems</italic></source>, <volume>6</volume>,
<fpage>13</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="pmid">29199020</pub-id></mixed-citation>
    </ref>
    <ref id="R22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname><given-names>S.</given-names></string-name>,
<string-name><surname>Thiessen</surname><given-names>P.A.</given-names></string-name>,
<string-name><surname>Cheng</surname><given-names>T.</given-names></string-name></person-group><etal>et al.</etal> (<year>2018</year>) <article-title>An update on PUG-REST:
restful interface for programmatic access to PubChem</article-title>.
<source><italic toggle="yes">Nucleic Acids Res.</italic></source>,
<volume>46</volume>,
<fpage>W563</fpage>–<lpage>W570</lpage>.<pub-id pub-id-type="pmid">29718389</pub-id></mixed-citation>
    </ref>
    <ref id="R23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname><given-names>S.</given-names></string-name>,
<string-name><surname>Chen</surname><given-names>J.</given-names></string-name>,
<string-name><surname>Cheng</surname><given-names>T.</given-names></string-name></person-group><etal>et al.</etal> (<year>2019</year>) <article-title>PubChem 2019 update:
improved access to chemical data</article-title>. <source><italic toggle="yes">Nucleic
Acids Res.</italic></source>, <volume>47</volume>,
<fpage>D1102</fpage>–<lpage>D1109</lpage>.<pub-id pub-id-type="pmid">30371825</pub-id></mixed-citation>
    </ref>
    <ref id="R24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fisher</surname><given-names>R.A.</given-names></string-name></person-group>
(<year>1922</year>) <article-title>On the interpretation of
χ<sup>2</sup> from contingency tables, and the calculation of
P</article-title>. <source><italic toggle="yes">J. R. Stat. Soc.</italic></source>,
<volume>85</volume>,
<fpage>87</fpage>–<lpage>94</lpage>.</mixed-citation>
    </ref>
    <ref id="R25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Corsello</surname><given-names>S.M.</given-names></string-name>,
<string-name><surname>Bittker</surname><given-names>J.A.</given-names></string-name>,
<string-name><surname>Liu</surname><given-names>Z.</given-names></string-name></person-group><etal>et al.</etal> (<year>2017</year>) <article-title>The Drug Repurposing Hub:
a next-generation drug library and information resource</article-title>.
<source><italic toggle="yes">Nat. Med.</italic></source>, <volume>23</volume>,
<fpage>405</fpage>–<lpage>408</lpage>.<pub-id pub-id-type="pmid">28388612</pub-id></mixed-citation>
    </ref>
    <ref id="R26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ursu</surname><given-names>O.</given-names></string-name>,
<string-name><surname>Holmes</surname><given-names>J.</given-names></string-name>,
<string-name><surname>Knockel</surname><given-names>J.</given-names></string-name></person-group><etal>et al.</etal> (<year>2016</year>)
<article-title>DrugCentral:onlinedrugcompendium</article-title>.<source><italic toggle="yes">NucleicAcidsRes.</italic></source>,<volume>45</volume>,<fpage>D932</fpage>–<lpage>D939</lpage>.</mixed-citation>
    </ref>
    <ref id="R27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fabian</surname><given-names>M.A.</given-names></string-name>,
<string-name><surname>Biggs</surname><given-names>W.H.</given-names></string-name>,
<string-name><surname>Treiber</surname><given-names>D.K.</given-names></string-name></person-group><etal>et al.</etal> (<year>2005</year>) <article-title>A small
molecule–kinase interaction map for clinical kinase
inhibitors</article-title>. <source><italic toggle="yes">Nat.
Biotechnol.</italic></source>, <volume>23</volume>,
<fpage>329</fpage>–<lpage>336</lpage>.<pub-id pub-id-type="pmid">15711537</pub-id></mixed-citation>
    </ref>
    <ref id="R28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lachmann</surname><given-names>A.</given-names></string-name>,
<string-name><surname>Schilder</surname><given-names>B.M.</given-names></string-name>,
<string-name><surname>Wojciechowicz</surname><given-names>M.L.</given-names></string-name></person-group><etal>et al.</etal> (<year>2019</year>) <article-title>Geneshot: search engine
for ranking genes from arbitrary text queries</article-title>.
<source><italic toggle="yes">Nucleic Acids Res.</italic></source>,
<volume>47</volume>,
<fpage>W571</fpage>–<lpage>W577</lpage>.<pub-id pub-id-type="pmid">31114885</pub-id></mixed-citation>
    </ref>
    <ref id="R29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Z.</given-names></string-name>,
<string-name><surname>Lachmann</surname><given-names>A.</given-names></string-name>,
<string-name><surname>Keenan</surname><given-names>A.B.</given-names></string-name></person-group><etal>et al.</etal> (<year>2018</year>) <article-title>L1000FWD: fireworks
visualization of drug-induced transcriptomic signatures</article-title>.
<source><italic toggle="yes">Bioinformatics</italic></source>, <volume>34</volume>,
<fpage>2150</fpage>–<lpage>2152</lpage>.<pub-id pub-id-type="pmid">29420694</pub-id></mixed-citation>
    </ref>
    <ref id="R30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Z.</given-names></string-name>,
<string-name><surname>Monteiro</surname><given-names>C.D.</given-names></string-name>,
<string-name><surname>Jagodnik</surname><given-names>K.M.</given-names></string-name></person-group><etal>et al.</etal> (<year>2016</year>) <article-title>Extraction and analysis
of signatures from the Gene Expression Omnibus by the crowd</article-title>.
<source><italic toggle="yes">Nat. Commun.</italic></source>, <volume>7</volume>,
<fpage>1</fpage>–<lpage>11</lpage>.</mixed-citation>
    </ref>
    <ref id="R31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kuhn</surname><given-names>M.</given-names></string-name>,
<string-name><surname>Letunic</surname><given-names>I.</given-names></string-name>,
<string-name><surname>Jensen</surname><given-names>L.J.</given-names></string-name></person-group><etal>et al.</etal> (<year>2016</year>) <article-title>The SIDER database of
drugs and side effects</article-title>. <source><italic toggle="yes">Nucleic Acids
Res.</italic></source>, <volume>44</volume>,
<fpage>D1075</fpage>–<lpage>D1079</lpage>.<pub-id pub-id-type="pmid">26481350</pub-id></mixed-citation>
    </ref>
    <ref id="R32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Z.</given-names></string-name>,
<string-name><surname>Clark</surname><given-names>N.R.</given-names></string-name>
and
<string-name><surname>Ma’ayan</surname><given-names>A.</given-names></string-name></person-group>
(<year>2016</year>) <article-title>Drug-induced adverse events prediction
with the LINCS L1000 data</article-title>.
<source><italic toggle="yes">Bioinformatics</italic></source>, <volume>32</volume>,
<fpage>2338</fpage>–<lpage>2345</lpage>.<pub-id pub-id-type="pmid">27153606</pub-id></mixed-citation>
    </ref>
    <ref id="R33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tatonetti</surname><given-names>N.P.</given-names></string-name>,
<string-name><surname>Patrick</surname><given-names>P.Y.</given-names></string-name>,
<string-name><surname>Daneshjou</surname><given-names>R.</given-names></string-name></person-group><etal>et al.</etal> (<year>2012</year>) <article-title>Data-driven prediction of
drug effects and interactions</article-title>. <source><italic toggle="yes">Sci. Transl.
Med.</italic></source>, <volume>4</volume>,
<fpage>125ra31</fpage>–<lpage>125ra31</lpage>.</mixed-citation>
    </ref>
    <ref id="R34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Consortium</surname><given-names>G.O.</given-names></string-name></person-group>
(<year>2019</year>) <article-title>The gene ontology resource: 20 years and
still GOing strong</article-title>. <source><italic toggle="yes">Nucleic Acids
Res.</italic></source>, <volume>47</volume>,
<fpage>D330</fpage>–<lpage>D338</lpage>.<pub-id pub-id-type="pmid">30395331</pub-id></mixed-citation>
    </ref>
    <ref id="R35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kanehisa</surname><given-names>M.</given-names></string-name>,
<string-name><surname>Goto</surname><given-names>S.</given-names></string-name>,
<string-name><surname>Kawashima</surname><given-names>S.</given-names></string-name></person-group><etal>et al.</etal> (<year>2004</year>) <article-title>The KEGG resource for
deciphering the genome</article-title>. <source><italic toggle="yes">Nucleic Acids
Res.</italic></source>, <volume>32</volume>,
<fpage>D277</fpage>–<lpage>D280</lpage>.<pub-id pub-id-type="pmid">14681412</pub-id></mixed-citation>
    </ref>
    <ref id="R36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Miller</surname><given-names>G.</given-names></string-name>
and
<string-name><surname>Britt</surname><given-names>H.</given-names></string-name></person-group>
(<year>1995</year>) <article-title>A new drug classification for computer
systems: the ATC extension code</article-title>. <source><italic toggle="yes">Int. J.
Biomed. Comput.</italic></source>, <volume>40</volume>,
<fpage>121</fpage>–<lpage>124</lpage>.<pub-id pub-id-type="pmid">8847119</pub-id></mixed-citation>
    </ref>
    <ref id="R37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Landrum</surname><given-names>G.</given-names></string-name></person-group>
(<year>2013</year>) <article-title>Rdkit documentation</article-title>.
<source><italic toggle="yes">Release</italic></source>, <volume>1</volume>,
<fpage>1</fpage>–<lpage>79</lpage>.</mixed-citation>
    </ref>
    <ref id="R38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Durant</surname><given-names>J.L.</given-names></string-name>,
<string-name><surname>Leland</surname><given-names>B.A.</given-names></string-name>,
<string-name><surname>Henry</surname><given-names>D.R.</given-names></string-name></person-group><etal>et al.</etal> (<year>2002</year>) <article-title>Reoptimization of MDL
keys for use in drug discovery</article-title>. <source><italic toggle="yes">J. Chem.
Inf. Comput. Sci.</italic></source>, <volume>42</volume>,
<fpage>1273</fpage>–<lpage>1280</lpage>.<pub-id pub-id-type="pmid">12444722</pub-id></mixed-citation>
    </ref>
    <ref id="R39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Clarke</surname><given-names>D.J.B.</given-names></string-name>,
<string-name><surname>Jeon</surname><given-names>M.</given-names></string-name>,
<string-name><surname>Stein</surname><given-names>D.J.</given-names></string-name></person-group><etal>et al.</etal> (<year>2021</year>) <article-title>Appyters: turning Jupyter
Notebooks into data driven web apps</article-title>.
<source><italic toggle="yes">Patterns (NY)</italic></source>, <volume>2</volume>,
<page-range>100213</page-range>.</mixed-citation>
    </ref>
    <ref id="R40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Subramanian</surname><given-names>A.</given-names></string-name>,
<string-name><surname>Narayan</surname><given-names>R.</given-names></string-name>,
<string-name><surname>Corsello</surname><given-names>S.M.</given-names></string-name></person-group><etal>et al.</etal> (<year>2017</year>) <article-title>A next generation
connectivity map: L1000 platform and the first 1,000,000
profiles</article-title>. <source><italic toggle="yes">Cell</italic></source>,
<volume>171</volume>,
<fpage>1437</fpage>–<lpage>1452.e1417</lpage>.<pub-id pub-id-type="pmid">29195078</pub-id></mixed-citation>
    </ref>
    <ref id="R41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bray</surname><given-names>M.-A.</given-names></string-name>,
<string-name><surname>Gustafsdottir</surname><given-names>S.M.</given-names></string-name>,
<string-name><surname>Rohban</surname><given-names>M.H.</given-names></string-name></person-group><etal>et al.</etal> (<year>2017</year>) <article-title>A dataset of images and
morphological profiles of 30 000 small-molecule treatments using the Cell
Painting assay</article-title>.
<source><italic toggle="yes">Gigascience</italic></source>, <volume>6</volume>,
<page-range>giw014</page-range>.</mixed-citation>
    </ref>
    <ref id="R42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pedregosa</surname><given-names>F.</given-names></string-name>,
<string-name><surname>Varoquaux</surname><given-names>G.</given-names></string-name>,
<string-name><surname>Gramfort</surname><given-names>A.</given-names></string-name></person-group><etal>et al.</etal> (<year>2011</year>) <article-title>Scikit-learn: machine
learning in Python</article-title>. <source><italic toggle="yes">J. Mach. Learn.
Res.</italic></source>, <volume>12</volume>,
<fpage>2825</fpage>–<lpage>2830</lpage>.</mixed-citation>
    </ref>
    <ref id="R43">
      <label>43.</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><collab>Team OpenAPI</collab></person-group>. (<year>2020</year>)
<italic toggle="yes">OpenAPI Specification. Version 3.0.3</italic>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://swagger.io/specification/" ext-link-type="uri">https://swagger.io/specification/</ext-link> (01 November 2020, date last
accessed).</mixed-citation>
    </ref>
    <ref id="R44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname><given-names>P.</given-names></string-name>,
<string-name><surname>Yang</surname><given-names>X.-L.</given-names></string-name>,
<string-name><surname>Wang</surname><given-names>X.-G.</given-names></string-name></person-group><etal>et al.</etal> (<year>2020</year>) <article-title>Discovery of a novel
coronavirus associated with the recent pneumonia outbreak in humans and its
potential bat origin</article-title>.
<source><italic toggle="yes">Nature</italic></source>., <volume>579</volume>,
<fpage>270</fpage>–<lpage>273</lpage>.<pub-id pub-id-type="pmid">32015507</pub-id></mixed-citation>
    </ref>
    <ref id="R45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>H.</given-names></string-name>,
<string-name><surname>Liu</surname><given-names>S.-M.</given-names></string-name>,
<string-name><surname>Yu</surname><given-names>X.-H.</given-names></string-name></person-group><etal>et al.</etal> (<year>2020</year>) <article-title>Coronavirus disease 2019
(COVID-19): current status and future perspective</article-title>.
<source><italic toggle="yes">Int. J. Antimicrob. Agents</italic></source>,
<volume>55</volume>, <page-range>105951</page-range>.</mixed-citation>
    </ref>
    <ref id="R46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kuleshov</surname><given-names>M.V.</given-names></string-name>,
<string-name><surname>Stein</surname><given-names>D.J.</given-names></string-name>,
<string-name><surname>Clarke</surname><given-names>D.J.B.</given-names></string-name></person-group><etal>et al.</etal> (<year>2020</year>) <article-title>The COVID-19 drug and
gene set library</article-title>. <source><italic toggle="yes">Patterns
(NY)</italic></source>, <volume>1</volume>,
<page-range>100090</page-range>.</mixed-citation>
    </ref>
    <ref id="R47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>C.Z.</given-names></string-name>,
<string-name><surname>Shinn</surname><given-names>P.</given-names></string-name>,
<string-name><surname>Itkin</surname><given-names>Z.</given-names></string-name></person-group><etal>et al.</etal> (<year>2020</year>) <article-title>Drug repurposing screen
for compounds inhibiting the cytopathic effect of
SARS-CoV-2</article-title>. <source><italic toggle="yes">Front. pharmacol</italic></source>.,
<volume>11</volume>, <page-range>2005</page-range>.</mixed-citation>
    </ref>
    <ref id="R48">
      <label>48.</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Dittmar</surname><given-names>M.</given-names></string-name>,
<string-name><surname>Lee</surname><given-names>J.S.</given-names></string-name>,
<string-name><surname>Whig</surname><given-names>K.</given-names></string-name></person-group><etal>et al.</etal> (<year>2020</year>) <article-title>Drug repurposing screens
reveal FDA approved drugs active against SARS-Cov-2</article-title>.
Available at <source>SSRN 3678908</source>.</mixed-citation>
    </ref>
    <ref id="R49">
      <label>49.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ellinger</surname><given-names>B.</given-names></string-name>,
<string-name><surname>Bojkova</surname><given-names>D.</given-names></string-name>,
<string-name><surname>Zaliani</surname><given-names>A.</given-names></string-name></person-group><etal>et al.</etal> (<year>2020</year>) <article-title>Identification of
inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells
using a large scale drug repurposing
collection</article-title>.</mixed-citation>
    </ref>
    <ref id="R50">
      <label>50.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ghahremanpour</surname><given-names>M.M.</given-names></string-name>,
<string-name><surname>Tirado-Rives</surname><given-names>J.</given-names></string-name>,
<string-name><surname>Deshmukh</surname><given-names>M.</given-names></string-name></person-group><etal>et al.</etal> (<year>2020</year>) <article-title>Identification of 14
known drugs as inhibitors of the main protease of
SARS-CoV-2</article-title>. <source><italic toggle="yes">ACS Med. Chem.
Lett</italic></source>, <volume>11</volume>,
<fpage>2526</fpage>–<lpage>2533</lpage>.<pub-id pub-id-type="pmid">33324471</pub-id></mixed-citation>
    </ref>
    <ref id="R51">
      <label>51.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Heiser</surname><given-names>K.</given-names></string-name>,
<string-name><surname>McLean</surname><given-names>P.F.</given-names></string-name>,
<string-name><surname>Davis</surname><given-names>C.T.</given-names></string-name></person-group><etal>et al.</etal> (<year>2020</year>) <article-title>Identification of
potential treatments for COVID-19 through artificial intelligence-enabled
phenomic analysis of human cells infected with SARS-CoV-2</article-title>.
<source><italic toggle="yes">bioRxiv</italic></source>.</mixed-citation>
    </ref>
    <ref id="R52">
      <label>52.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname><given-names>R.</given-names></string-name>,
<string-name><surname>Xu</surname><given-names>M.</given-names></string-name>,
<string-name><surname>Zhu</surname><given-names>H.</given-names></string-name></person-group><etal>et al.</etal> (<year>2021</year>) <article-title>Massive-scale biological
activity-based modeling identifies novel antiviral leads against
SARS-CoV-2</article-title>. <source><italic toggle="yes">Nat
Biotechnol</italic></source>.</mixed-citation>
    </ref>
    <ref id="R53">
      <label>53.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jeon</surname><given-names>S.</given-names></string-name>,
<string-name><surname>Ko</surname><given-names>M.</given-names></string-name>,
<string-name><surname>Lee</surname><given-names>J.</given-names></string-name></person-group><etal>et al.</etal> (<year>2020</year>) <article-title>Identification of
antiviral drug candidates against SARS-CoV-2 from FDA-approved
drugs</article-title>. <source><italic toggle="yes">Antimicrob. Agents
Chemother</italic></source>., <volume>64</volume>,
<fpage>e00819</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="pmid">32366720</pub-id></mixed-citation>
    </ref>
    <ref id="R54">
      <label>54.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mirabelli</surname><given-names>C.</given-names></string-name>,
<string-name><surname>Wotring</surname><given-names>J.W.</given-names></string-name>,
<string-name><surname>Zhang</surname><given-names>C.J.</given-names></string-name></person-group><etal>et al.</etal> (<year>2020</year>) <article-title>Morphological cell
profiling of SARS-CoV-2 infection identifies drug repurposing candidates for
COVID-19</article-title>.
<source><italic toggle="yes">bioRxiv</italic></source>.</mixed-citation>
    </ref>
    <ref id="R55">
      <label>55.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Riva</surname><given-names>L.</given-names></string-name>,
<string-name><surname>Yuan</surname><given-names>S.</given-names></string-name>,
<string-name><surname>Yin</surname><given-names>X.</given-names></string-name></person-group><etal>et al.</etal> (<year>2020</year>) <article-title>Discovery of SARS-CoV-2
antiviral drugs through large-scale compound repurposing</article-title>.
<source><italic toggle="yes">Nature</italic></source>, <volume>586</volume>,
<fpage>113</fpage>–<lpage>119</lpage>.<pub-id pub-id-type="pmid">32707573</pub-id></mixed-citation>
    </ref>
    <ref id="R56">
      <label>56.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Touret</surname><given-names>F.</given-names></string-name>,
<string-name><surname>Gilles</surname><given-names>M.</given-names></string-name>,
<string-name><surname>Barral</surname><given-names>K.</given-names></string-name></person-group><etal>et al.</etal> (<year>2020</year>) <article-title>In vitro screening of a
FDA approved chemical library reveals potential inhibitors of SARS-CoV-2
replication</article-title>. <source><italic toggle="yes">Sci. Rep.</italic></source>,
<volume>10</volume>,
<fpage>1</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">31913322</pub-id></mixed-citation>
    </ref>
    <ref id="R57">
      <label>57.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Weston</surname><given-names>S.</given-names></string-name>,
<string-name><surname>Coleman</surname><given-names>C.M.</given-names></string-name>,
<string-name><surname>Sisk</surname><given-names>J.M.</given-names></string-name></person-group><etal>et al.</etal> (<year>2020</year>) <article-title>Broad anti-coronaviral
activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in
vivo</article-title>. <source><italic toggle="yes">bioRxiv, J. Virol</italic></source>.,
<volume>94</volume>, <page-range>21</page-range>.</mixed-citation>
    </ref>
    <ref id="R58">
      <label>58.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xiao</surname><given-names>X.</given-names></string-name>,
<string-name><surname>Wang</surname><given-names>C.</given-names></string-name>,
<string-name><surname>Chang</surname><given-names>D.</given-names></string-name></person-group><etal>et al.</etal> (<year>2020</year>) <article-title>Identification of potent
and safe antiviral therapeutic candidates against
SARS-CoV-2</article-title>. <source><italic toggle="yes">bioRxiv, Front.
Immunol</italic></source>., <volume>11</volume>,
<page-range>586572</page-range>.</mixed-citation>
    </ref>
    <ref id="R59">
      <label>59.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoagland</surname><given-names>D.A.</given-names></string-name>,
<string-name><surname>Clarke</surname><given-names>D.J.B.</given-names></string-name>,
<string-name><surname>Møller</surname><given-names>R.</given-names></string-name></person-group><etal>et al.</etal> (<year>2020</year>) <article-title>Modulating the
transcriptional landscape of SARS-CoV-2 as an effective method for
developing antiviral compounds</article-title>.
<source><italic toggle="yes">bioRxiv</italic></source>.doi: <pub-id pub-id-type="doi">10.1101/2020.07.12.199687</pub-id></mixed-citation>
    </ref>
    <ref id="R60">
      <label>60.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Quasthoff</surname><given-names>S.</given-names></string-name>
and
<string-name><surname>Hartung</surname><given-names>H.P.</given-names></string-name></person-group>
(<year>2002</year>) <article-title>Chemotherapy-induced peripheral
neuropathy</article-title>. <source><italic toggle="yes">J. Neurol.</italic></source>,
<volume>249</volume>,
<fpage>9</fpage>–<lpage>17</lpage>.<pub-id pub-id-type="pmid">11954874</pub-id></mixed-citation>
    </ref>
    <ref id="R61">
      <label>61.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boulton</surname><given-names>A.J.</given-names></string-name></person-group>
(<year>2005</year>) <article-title>Management of diabetic peripheral
neuropathy</article-title>. <source><italic toggle="yes">Clin.
Diabetes</italic></source>, <volume>23</volume>,
<fpage>9</fpage>–<lpage>15</lpage>.</mixed-citation>
    </ref>
    <ref id="R62">
      <label>62.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>H.Y.Z.</given-names></string-name>,
<string-name><surname>Pavel</surname><given-names>M.A.</given-names></string-name>
and
<string-name><surname>Hansen</surname><given-names>S.B.</given-names></string-name></person-group>
(<year>2020</year>) <article-title>Cholesterol and COVID19 lethality in
elderly</article-title>.
<source><italic toggle="yes">bioRxiv</italic></source>.</mixed-citation>
    </ref>
    <ref id="R63">
      <label>63.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cyster</surname><given-names>J.G.</given-names></string-name>,
<string-name><surname>Dang</surname><given-names>E.V.</given-names></string-name>,
<string-name><surname>Reboldi</surname><given-names>A.</given-names></string-name></person-group><etal>et al.</etal> (<year>2014</year>) <article-title>25-Hydroxycholesterols in
innate and adaptive immunity</article-title>. <source><italic toggle="yes">Nat. Rev.
Immunol.</italic></source>, <volume>14</volume>,
<fpage>731</fpage>–<lpage>743</lpage>.<pub-id pub-id-type="pmid">25324126</pub-id></mixed-citation>
    </ref>
    <ref id="R64">
      <label>64.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname><given-names>W.</given-names></string-name>,
<string-name><surname>Ahn</surname><given-names>J.H.</given-names></string-name>,
<string-name><surname>Park</surname><given-names>H.H.</given-names></string-name></person-group><etal>et al.</etal> (<year>2020</year>) <article-title>COVID-19-activated SREBP2
disturbs cholesterol biosynthesis and leads to cytokine
storm</article-title>. <source><italic toggle="yes">Signal Transduct. Target.
Ther.</italic></source>, <volume>5</volume>,
<fpage>1</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="pmid">32296011</pub-id></mixed-citation>
    </ref>
    <ref id="R65">
      <label>65.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>X.-J.</given-names></string-name>,
<string-name><surname>Qin</surname><given-names>J.-J.</given-names></string-name>,
<string-name><surname>Cheng</surname><given-names>X.</given-names></string-name></person-group><etal>et al.</etal> (<year>2020</year>) <article-title>In-hospital use of
statins is associated with a reduced risk of mortality among individuals
with COVID-19</article-title>. <source><italic toggle="yes">Cell
Metab.</italic></source>, <volume>32</volume>,
<fpage>176</fpage>–<lpage>187.e174</lpage>.<pub-id pub-id-type="pmid">32592657</pub-id></mixed-citation>
    </ref>
    <ref id="R66">
      <label>66.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Castiglione</surname><given-names>V.</given-names></string-name>,
<string-name><surname>Chiriacò</surname><given-names>M.</given-names></string-name>,
<string-name><surname>Emdin</surname><given-names>M.</given-names></string-name></person-group><etal>et al.</etal> (<year>2020</year>) <article-title>Statin therapy in
COVID-19 infection</article-title>. <source><italic toggle="yes">Eur. Heart J.
Cardiovasc. Pharmacother</italic></source>., <volume>6</volume>,
<fpage>258</fpage>–<lpage>259</lpage>.<pub-id pub-id-type="pmid">32347925</pub-id></mixed-citation>
    </ref>
    <ref id="R67">
      <label>67.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bifulco</surname><given-names>M.</given-names></string-name>
and
<string-name><surname>Gazzerro</surname><given-names>P.</given-names></string-name></person-group>
(<year>2020</year>) <article-title>Statin therapy in COVID-19 infection:
much more than a single pathway</article-title>. <source><italic toggle="yes">Eur. Heart
J. Cardiovasc. Pharmacother.</italic></source></mixed-citation>
    </ref>
    <ref id="R68">
      <label>68.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Daniels</surname><given-names>L.B.</given-names></string-name>,
<string-name><surname>Sitapati</surname><given-names>A.M.</given-names></string-name>,
<string-name><surname>Zhang</surname><given-names>J.</given-names></string-name></person-group><etal>et al.</etal> (<year>2020</year>) <article-title>Relation of statin use
prior to admission to severity and recovery among COVID-19
inpatients</article-title>. <source><italic toggle="yes">Am. J.
Cardiol</italic></source>., <volume>136</volume>,
<fpage>149</fpage>–<lpage>155</lpage>.<pub-id pub-id-type="pmid">32946859</pub-id></mixed-citation>
    </ref>
    <ref id="R69">
      <label>69.</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Kropiwnicki</surname><given-names>E.</given-names></string-name></person-group>
(<year>2020</year>) <source><italic toggle="yes">Integration and Abstraction of Small
Molecule Attributes for Drug Enrichment Analysis</italic></source>.
<publisher-name>(Thesis) Icahn School of Medicine at Mount Sinai, NY,
USA</publisher-name>.</mixed-citation>
    </ref>
    <ref id="R70">
      <label>70.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tsai</surname><given-names>J.</given-names></string-name>,
<string-name><surname>Lee</surname><given-names>J.T.</given-names></string-name>,
<string-name><surname>Wang</surname><given-names>W.</given-names></string-name></person-group><etal>et al.</etal> (<year>2008</year>) <article-title>Discovery of a selective
inhibitor of oncogenic B-Raf kinase with potent antimelanoma
activity</article-title>. <source><italic toggle="yes">Proc. Natl. Acad. Sci.
U.S.A.</italic></source>, <volume>105</volume>,
<fpage>3041</fpage>–<lpage>3046</lpage>.<pub-id pub-id-type="pmid">18287029</pub-id></mixed-citation>
    </ref>
    <ref id="R71">
      <label>71.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kametani</surname><given-names>T.</given-names></string-name>,
<string-name><surname>Nemoto</surname><given-names>H.</given-names></string-name>,
<string-name><surname>Takeda</surname><given-names>H.</given-names></string-name></person-group><etal>et al.</etal> (<year>1970</year>) <article-title>A synthetic approach to
camptothecin</article-title>. <source><italic toggle="yes">Chem. Ind.</italic></source>,
<volume>41</volume>,
<fpage>1323</fpage>–<lpage>1324</lpage>.<pub-id pub-id-type="pmid">5482351</pub-id></mixed-citation>
    </ref>
    <ref id="R72">
      <label>72.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gökbuget</surname><given-names>N.</given-names></string-name>
and
<string-name><surname>Hoelzer</surname><given-names>D.</given-names></string-name></person-group>
(<year>1997</year>) <article-title>Vindesine in the treatment of
leukaemia</article-title>. <source><italic toggle="yes">Leuk. Lymphoma</italic></source>,
<volume>26</volume>,
<fpage>497</fpage>–<lpage>506</lpage>.<pub-id pub-id-type="pmid">9389357</pub-id></mixed-citation>
    </ref>
    <ref id="R73">
      <label>73.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Doldo</surname><given-names>E.</given-names></string-name>,
<string-name><surname>Costanza</surname><given-names>G.</given-names></string-name>,
<string-name><surname>Agostinelli</surname><given-names>S.</given-names></string-name>,
<string-name><surname>Tarquini</surname><given-names>C.</given-names></string-name>,
<string-name><surname>Ferlosio</surname><given-names>A.</given-names></string-name>,
<string-name><surname>Arcuri</surname><given-names>G.</given-names></string-name>,
<etal>et al.</etal></person-group> (<year>2015</year>)
<article-title>Vitamin A, cancer treatment and prevention: the new role of
cellular retinol binding proteins</article-title>. <source><italic toggle="yes">Biomed
Res Int</italic></source>., <volume>2015</volume>,
<page-range>624627</page-range>.</mixed-citation>
    </ref>
  </ref-list>
</back>
